Начало >> Статьи >> Литература >> Ведение пациентов с нестабильной стенокардией / инфарктом миокарда без подъема сегмента ST

Литература - Ведение пациентов с нестабильной стенокардией / инфарктом миокарда без подъема сегмента ST

Оглавление
Ведение пациентов с нестабильной стенокардией / инфарктом миокарда без подъема сегмента ST
Введение
Обзор острых коронарных синдромов
Ведение пациентов до развития НС/ИМ БП ST и его проявление
Проявления НС/ИМ БП ST
Клиническая оценка состояния
Ранняя стратификация риска
Ведение пациентов в раннем периоде
Антиишемическая и антиангинальная терапия в стационаре на раннем этапе
Рекомендации по антитромботической/антикоагулянтной терапии
Рекомендации по антитромботической/антикоагулянтной терапии - антитромботические препараты
Рекомендации по антитромботической/антикоагулянтной терапии - антикоагулянтные препараты
Антагонисты IIb/IIIa гликопротеиновых рецепторов тромбоцитов
Первичная консервативная стратегия по сравнению с первичной инвазивной
Стратификация риска перед выпиской
Рекомендации по реваскуляризации
Общие принципы коронарной реваскуляризации
Чрескожное коронарное вмешательство
Хирургическая коронарная реваскуляризация
Режим медикаментозного лечения на позднем этапе и применение препаратов
Последующее наблюдение после выписки из стационара
Сердечная реабилитация после выписки из стационара
После выписки из стационара - возвращение к работе, инвалидность, медицинские карты пациентов
Особые группы - женщины
Особые группы - диабетики
Особые группы - пациенты, ранее перенесшие КШ
Особые группы - пожилые пациенты
Особые группы - пациенты с хронической болезнью почек
Особые группы - пациенты, употребляющие кокаин и метамфетамин
Особые группы - пациенты со стенокардией Принцметала
Особые группы - пациенты с сердечно-сосудистым Синдромом Х и кардиомиопатией тако-тсубо
Выводы и дальнейшие направления развития
Литература

ЛИТЕРАТУРА

  1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction) J Am Coll Cardiol 2004;44:e1-e211.
  2. Smith Jr. SC, Feldman TE, Hirshfeld Jr. JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) J Am Coll Cardiol 2006;47:e1-e121.
  3. Smith Jr. SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute J Am Coll Cardiol 2006;47:2130-2139.
  4. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). Доступно на: http://www.acc.org/qualityandscience. Действительно на 8 мая 2007.
  5. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 2007;115:e69-e171.
  6. National Heart Attack Alert Program. Emergency Department: rapid identification and treatment of patients with acute myocardial infarction. US Department of Health and Human Services. US Public Health Service. National Institutes of Health. National Heart, Lung and Blood Institute; September 1993; NIH Publication No. 93-3278.
  7. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes Circulation 2001;104:365-372.
  8. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines Lancet 2001;358:1533-1538.
  9. Davies MJ. The pathophysiology of acute coronary syndromes Heart 2000;83:361-366.
  10. . Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction J Am Coll Cardiol 1995;26:1643-1650.
  11. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes RJ. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases Clin Chem 1999;45:1104-1121.
  12. Braunwald E. Unstable angina: an etiologic approach to management [editorial] Circulation 1998;98:2219-2222.
  13. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q-wave myocardial infarction N Engl J Med 1986;315:417-423.
  14. Braunwald E. Unstable angina: a classification Circulation 1989;80:410-414.
  15. Campeau L. Letter: grading of angina pectoris Circulation 1976;54:522-523.
  16. 41318. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004;110:227-239.
  17. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 2002;106:3143-3421.
  18. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001;285:2486-2497.
  19. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 2006; 113:791-798.
  20. Ebrahim S, Davey SG. Multiple risk factor interventions for primary prevention of coronary heart disease Cochrane Database Syst Rev 2000CD001561.
  21. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta­analysis Arch Intern Med 1999;159:1793-1802.
  22. Grundy SM, Pasternak R, Greenland P, Smith Jr. S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology Circulation 1999;100:1481-1492.
  23. American Heart Association. Risk Assessment. Доступно на: http://www.americanheart.org/presenter.jhtml?identifier=3003499. Действительно на 7 августа 2006.
  24. Pearson ТА, Blair SN, Daniels SR, et al. American Heart Association Science Advisory and Coordinating Committee AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases Circulation 2002;106:388-391.
  25. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology Circulation 2006;114:1761-1791.
  26. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies Arch Intern Med 2000;160:939-944.
  27. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 1999;318:1730-1737.
  28. Smith Jr. SC, Blair SN, Bonow RO, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology Circulation 2001;104:1577-1579.
  29. Mosca L, American Heart Association Cardiology patient page Heart disease prevention in women. Circulation 2004;109:el58-el60.
  30. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study Lancet 2006;368:647-658.
  31. Office of the Surgeon General. Treating tobacco use and dependence: a clinical practice guideline. Доступно на: http://www.surgeongeneral.gov/tobacco, 2000. Действительно на 17 июля 2006.
  32. Tonstad S, Tonnesen Р, Hajek Р, Williams КЕ, Billing СВ, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial JAMA 2006;296:64-71.
  33. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial JAMA 2006;296:56-63.
  34. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial JAMA 2006;296:47-55.
  35. 1. U.S. Food and Drug Administration. FDA News. FDA Approves Novel Medication for Smoking            Cessation.                       May                                11,                        2006.               Доступно           на:
  36. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01370.html. Действительно на 15 августа 2006.
  37. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations Ann Intern Med 2006;145:845- 856.
  38. National Institutes of Health state-of-the-science conference statement: tobacco use: prevention, cessation, and control Ann Intern Med 2006;145:839-844.
  39. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women J Am Coll Cardiol 2007;49:1230-1250.
  40. Brown DJ. New guidelines for low-density lipoprotein levels from the National Cholesterol Education Program (NCEP): a 2004 update Prog Cardiovasc Nurs 2004;19:165.
  41. National Institutes of Health Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report Obes Res 1998;6(Suppl 2):51S-209S.
  42. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Cholesterol with Therapeutic Lifestyle Changes. NIH Publication No. 06-5235. December 2005. Доступно на: http://www.nhlbi.nih.gov/health/public/heart/chol/chol_tlc.pdf. Действительно на 27 ноября 2006. 1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 2003;289:2560-2572.
  43. Pignone M, Mulrow CD. Evidence based management of hypertension: Using cardiovascular risk profiles to individualize hypertensive treatment BMJ 2001;322:1164-1166.
  44. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee Circulation 2006;114:82-96.
  45. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) Circulation 2003;107:3109-3116.
  46. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation 2006;113:898-918.
  47. Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation Circulation 2005;111:369-376.
  48. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 2003;362:1527- 1535.
  49. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
  50. Grundy SM, Howard B, Smith Jr. S, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association Circulation 2002;105:2231-2239.
  51. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association Circulation 2006;113:2943-2946.
  52. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 2002;136:161-172.
  53. U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: recommendation and rationale Ann Intern Med 2002;136:157-160.
  54. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 2003;108:1682-1687.
  55. Hung J. Aspirin for cardiovascular disease prevention Med J Aust 2003;179:147-152.
  56. Abidov A, Rozanski A, Hachamovitch R, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing N Engl J Med 2005;353:1889-1898.
  57. Goff Jr. DC, Sellers DE, McGovern PG, et al. Knowledge of heart attack symptoms in a population survey in the United States: the REACT TrialRapid Early Action for Coronary Treatment. Arch Intern Med 1998;158:2329-2338.
  58. Goff Jr. DC, Feldman HA, McGovern PG, et al. Rapid Early Action for Coronary Treatment (REACT) Study Group Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial Am Heart J 1999;138:1046-1057.
  59. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3 J Am Coll Cardiol 2000;36:2056-2063.
  60. Welsh RC, Ornato J, Armstrong PW. Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America Am Heart J 2003;145:1-8.
  61. Goldberg RJ, Steg PG, Sadiq I, et al. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry) Am J Cardiol 2002;89:791-796.
  62. Finnegan Jr. JR, Meischke H, Zapka JG, et al. Patient delay in seeking care for heart attack symptoms: findings from focus groups conducted in five U.S. regions Prev Med 2000;31:205-213.
  63. Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: the Rapid Early Action for Coronary Treatment (REACT) trial JAMA 2000;284:60-67.
  64. Feldman HA, Proschan MA, Murray DM, et al. Statistical design of REACT (Rapid Early Action for Coronary Treatment), a multisite community trial with continual data collection Control Clin Trials 1998;19:391-403.
  65. Leslie WS, Urie A, Hooper J, Morrison CE. Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care Heart 2000;84:137-141.
  66. McKinley S, Moser DK, Dracup K. Treatment-seeking behavior for acute myocardial infarction symptoms in North America and Australia Heart Lung 2000;29:237-247.
  67. Rucker D, Brennan T, Burstin H. Delay in seeking emergency care Acad Emerg Med 2001;8:163-169.
  68. ссылка удалена.
  69. Moser DK, Kimble LP, Alberts MJ, et al. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council Circulation 2006;114:168-182.
  70. Sheifer SE, Gersh BJ, Yanez III ND, Ades PA, Burke GL, Manolio TA. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly J Am Coll Cardiol 2000;35:119-126.
  71. Kannel WB. Silent myocardial ischemia and infarction: insights from the Framingham Study Cardiol Clin 1986;4:583-591.
  72. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain JAMA 2000;283:3223- 3229.
  73. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Treatment of patients with myocardial infarction who present with a paced rhythm Ann Intern Med 2001;134:644-651.
  74. Dracup K, Alonzo AA, Atkins JM, et al. Working Group on Educational Strategies To Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction The physician’s role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program Ann Intern Med 1997;126:645-651.
  75. Selker HP, Beshansky JR, Griffith JL, et al. Use of the acute cardiac ischemia time- insensitive predictive instrument (ACI-TIPI) to assist with triage of patients with chest pain or other symptoms suggestive of acute cardiac ischemia: a multicenter, controlled clinical trial Ann Intern Med 1998;129:845-855.
  76. Faxon D, Lenfant C. Timing is everything: motivating patients to call 9—1—1 at onset of acute myocardial infarction Circulation 2001;104:1210-1211.
  77. National Heart, Lung and Blood Institute, National Institutes of Health. Act in Time to Heart Attack Signs. Доступно на: http://www.nhlbi.nih.gov/health/public/heart/mi/core_pk.pdf. Действительно на 27 ноября 2006.
  78. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung and Blood Institute. NIH Publication No. 01-3525. September 2001. http://www.nhlbi.nih.gov/health/public/heart/mi/core_bk.pdf. Действительно на 17 июля 2006.
  79. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung and Blood Institute. NIH Publication No. 01-3526. September 2001. Доступно на: http://www.nhlbi.nih.gov/health/public/heart/mi/core_sp.pdf. Действительно на 17 июля 2006.
  80. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung and Blood Institute. NIH Publication No. 01-3667. September 2001. Доступно на: http://www.nhlbi.nih.gov/health/public/heart/mi/wallet.pdf. Действительно на 17 июля 2006.
  81. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung and Blood Institute. NIH Publication No. 01—3669. September 2001. Доступно на: http://www.nhlbi.nih.gov/health/public/heart/mi/act_plan.pdf. Действительно на 17 июля 2006.
  82. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung and Blood Institute. NIH Publication No. 01-3313. September 2001. Доступно на: http://www.nhlbi.nih.gov/health/prof/heart/mi/provider.pdf. Действительно на 17 июля 2006.
  83. Department of Health and Human Services. Act in Time to Heart Attack Signs: Physician Quick Reference Tool for Palm OS. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. 2001. Доступно на: http://hin.nhlbi.nih.gov/haac_palm/haac_palm.htm. Действительно на 17 июля 2006.
  84. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung and Blood Institute. NIH Publication No. 01-3646. September 2001. Доступно на: http://www.nhlbi.nih.gov/health/public/heart/mi/poster.pdf. Действительно на 17 июля 2006.
  85. Ghali JK, Cooper RS, Kowatly I, Liao Y. Delay between onset of chest pain and arrival to the coronary care unit among minority and disadvantaged patients J Natl Med Assoc 1993;85:180-184.
  86. Hargarten K, Chapman PD, Stueven HA, et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain Ann Emerg Med 1990;19:1274-1279.
  87. Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient Ann Emerg Med 1997;29:116-125.
  88. Tatum JL. Cost effective nuclear scanning in a comprehensive and systematic approach to the evaluation of chest pain in the emergency department Md Med J 1997(Suppl):25-29.
  89. Ornato JP. Chest pain emergency centers: improving acute myocardial infarction care Clin Cardiol 1999;22:IV3-IV9.
  90. Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study Circulation 2001;103:1832-1837.
  91. Lateef F, Storrow AB, Gibler BW, Liu T. Heart emergency room: effective for both geriatric and younger patients Singapore Med J 2001;42:259-263.
  92. Lateef F, Storrow AB, Malone K, Liu T, Gibler BW. Comparison of a 6-hour and 9-hour protocol for evaluation of moderate-to-low risk chest pain patients in an emergency department diagnostic unit Singapore Med J 2001;42:52-56.
  93. Gibler WB. Chest pain evaluation in the ED: beyond triage Am J Emerg Med 1994; 12:121­122.
  94. Gibler WB. Evaluation of chest pain in the emergency department Ann Intern Med 1995;123:315-318.
  95. Gibler WB. Chest pain units: do they make sense now? Ann Emerg Med 1997;29:168-171.
  96. Gibler WB. Evaluating patients with chest pain in the ED: improving speed, efficiency, and cost-effectiveness, or teaching an old dog new tricks Ann Emerg Med 1994;23:381-382.
  97. Hoekstra JW, Gibler WB, Levy RC, et al. Emergency-department diagnosis of acute myocardial infarction and ischemia: a cost analysis of two diagnostic protocols Acad Emerg Med 1994;1:103-110.
  98. Hoekstra JW, Hedges JR, Gibler WB, Rubison RM, Christensen RA, National Cooperative CK-MB Project Group Emergency department CK-MB: a predictor of ischemic complications Acad Emerg Med 1994;1:17-27.
  99. Cannon CP, Hand MH, Bahr R, et al. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program Am Heart J 2002;143:777-789.
  100. Zalenski RJ, Selker HP, Cannon CP, et al. National Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemia Ann Emerg Med 2000;35:462-471.
  101. Lambrew CT, Weaver WD, Rogers WJ, Bowlby LJ, Rubison RM, French WJ. Hospital protocols and policies that may delay early identification and thrombolytic therapy of acute myocardial infarction patients J Thromb Thrombolysis 1996;3:301-306.
  102. Farkouh ME, Smars PA, Reeder GS, et al. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators A clinical trial of a chest-pain observation unit for patients with unstable angina N Engl J Med 1998;339:1882-1888.
  103. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction —summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) J Am Coll Cardiol 2002;40:1366-1374.
  104. Hedges JR, Feldman HA, Bittner V, et al. REACT Study Group Impact of community intervention to reduce patient delay time on use of reperfusion therapy for acute myocardial infarction: rapid early action for coronary treatment (REACT) trial Acad Emerg Med 2000;7:862- 872.
  105. Canto JG, Zalenski RJ, Ornato JP, et al. Use of emergency medical services in acute myocardial infarction and subsequent quality of care: observations from the National Registry of Myocardial Infarction 2 Circulation 2002;106:3018-3023.
  106. Goldberg R, Goff D, Cooper L, et al. Age and sex differences in presentation of symptoms among patients with acute coronary disease: the REACT TrialRapid Early Action for Coronary Treatment. Coron Artery Dis 2000;11:399-407.
  107. Hutchings CB, Mann NC, Daya M, et al. Patients with chest pain calling 9-1-1 or self­transporting to reach definitive care: which mode is quicker? Am Heart J 2004;147:35-41.
  108. Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest during self-transport for chest pain Ann Emerg Med 1996;18:612-616.
  109. Brown AL, Mann NC, Daya M, et al. Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patientsRapid Early Action for Coronary Treatment (REACT) study. Circulation 2000;102:173-178.
  110. Herlitz J, Karlson BW, Liljeqvist JA, Strombom U, Holmberg S. Early identification of acute myocardial infarction and prognosis in relation to mode of transport to hospital Am J Emerg Med 1992;10:406-412.
  111. Ho MT, Eisenberg MS, Litwin PE, Schaeffer SM, Damon SK. Delay between onset of chest pain and seeking medical care: the effect of public education Ann Emerg Med 1989;18:727-731.
  112. Dracup K, Moser DK, Eisenberg M, Meischke H, Alonzo AA, Braslow A. Causes of delay in seeking treatment for heart attack symptoms Soc Sci Med 1995;40:379-392.
  113. Herlitz J, Blohm M, Hartford M, et al. Follow-up of a 1-year media campaign on delay times and ambulance use in suspected acute myocardial infarction Eur Heart J 1992;13:171-177.
  114. Wright RS, Kopecky SL, Timm M, et al. Impact of community-based education on health care evaluation in patients with acute chest pain syndromes: the Wabasha Heart Attack Team (WHAT) project Fam Pract 2001;18:537-539.
  115. Hand M, Brown C, Horan M, Simons-Morton D. Access to timely and optimal care of patients with acute coronary syndromes—community planning considerations: a report by the National Heart Attack Alert Program J Thromb Thrombolysis 1998;6:19-46.
  116. Simon AB, Feinleib M, Thompson Jr. HK. Components of delay in the pre-hospital phase of acute myocardial infarction Am J Cardiol 1972;30:476-482.
  117. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Доступно на: http://www.acc.org/clinical/guidelines/ami.html. Действительно на: September 1, 1999.
  118. Alonzo AA. The impact of the family and lay others on care-seeking during life-threatening episodes of suspected coronary artery disease Soc Sci Med 1986;22:1297-1311.
  119. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular carePart 7: the era of reperfusion: section 1: acute coronary syndromes (acute myocardial infarction). Circulation 2000;102:I172-I203.
  120. McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease Arch Intern Med 2003;163:2157-2162.
  121. Newby LK, Califf RM, Guerci A, et al. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial J Am Coll Cardiol 1996;27:625-632.
  122. Maynard C, Weaver WD, Lambrew C, Bowlby LJ, Rogers WJ, Rubison RM, Participants in the National Registry of Myocardial Infarction Factors influencing the time to administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction) Am J Cardiol 1995;76:548-552.
  123. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial JAMA 1993;270:1211-1216.
  124. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. 3­1-1994; AHCPR Publication No. 94-0602:1—154.
  125. Pope JH, Ruthazer R, Beshansky JR, Griffith JL, Selker HP. Clinical features of emergency department patients presenting with symptoms suggestive of acute cardiac ischemia: a multicenter study J Thromb Thrombolysis 1998;6:63-74.
  126. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction Circulation 1998;97:1195-1206.
  127. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes JAMA 1999;281:707-713.
  128. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromesPlatelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-443.
  129. The TIMI IIIB Investigators Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB TrialThrombolysis in Myocardial Ischemia. Circulation 1994;89:1545-1556.
  130. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction(published erratum appears in N Engl J Med 1998;339:415) N Engl J Med 1998;338:1488-1497.
  131. Chang WC, Boersma E, Granger CB, et al. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT Am Heart J 2004;148:62-71.
  132. Ronner E, Boersma E, Laarman GJ, et al. Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT trialPlatelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. J Am Coll Cardiol 2002;39:1924-1929.
  133. Theroux P, Alexander Jr. J, Pharand C, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study Circulation 2000;102:2466-2472.
  134. Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS trial Circulation 1999;100:1609-1615.
  135. Chaitman BR, Bourassa MG, Davis K, et al. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS) Circulation 1981;64:360-367.
  136. Pryor DB, Harrell FEJ, Lee KL, Califf RM, Rosati RA. Estimating the likelihood of significant coronary artery disease Am J Med 1983;75:771-780.
  137. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease Ann Intern Med 1993;118:81-90.
  138. Morise AP, Haddad WJ, Beckner D. Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease Am J Med 1997;102:350-356.
  139. Ho KT, Miller TD, Hodge DO, Bailey KR, Gibbons RJ. Use of a simple clinical score to predict prognosis of patients with normal or mildly abnormal resting electrocardiographic findings undergoing evaluation for coronary artery disease Mayo Clin Proc 2002;77:515-521.
  140. Kasser IS, Bruce RA. Comparative effects of aging and coronary heart disease on submaximal and maximal exercise Circulation 1969;39:759-774.
  141. Patel H, Rosengren A, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference? Am Heart J 2004;148:27-33.
  142. McSweeney JC, Cody M, O’Sullivan P, Elberson K, Moser DK, Garvin BJ. Women’s early warning symptoms of acute myocardial infarction Circulation 2003;108:2619-2623.
  143. Lee TH, Cook EF, Weisberg M, Sargent RK, Wilson C, Goldman L. Acute chest pain in the emergency room: identification and examination of low-risk patients Arch Intern Med 1985; 145:65­
  144. 69.
  145. Pozen MW, D’Agostino RB, Selker HP, Sytkowski PA, Hood WBJ. A predictive instrument to improve coronary-care-unit admission practices in acute ischemic heart disease: a prospective multicenter clinical trial N Engl J Med 1984;310:1273-1278.
  146. Selker HP, Griffith JL, D’Agostino RB. A tool for judging coronary care unit admission appropriateness, valid for both real-time and retrospective useA time-insensitive predictive instrument (TIPI) for acute cardiac ischemia: a multicenter study. (published erratum appears in Med Care 1992;30:188) Med Care 1991;29:610-627.
  147. Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease Ann Intern Med 2003;139:979-986.
  148. Swap CJ, Nagurney JT. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes JAMA 2005;294:2623-2629.
  149. Brieger DB, Mak KH, White HD, et al. Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial): Global Utilization of Streptokinase and TPA for occluded arteries Am J Cardiol 1998;81:282-287.
  150. Hochman JS, Tamis JE, Thompson TD, et al. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators Sex, clinical presentation, and outcome in patients with acute coronary syndromes N Engl J Med 1999;341:226-232.
  151. Hochman JS, McCabe CH, Stone PH, et al. TIMI Investigators Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIBThrombolysis in Myocardial Infarction. J Am Coll Cardiol 1997;30:141-148.
  152. Scirica BM, Moliterno DJ, Every NR, et al. The GUARANTEE Investigators Differences between men and women in the management of unstable angina pectoris (the GUARANTEE registry) Am J Cardiol 1999;84:1145-1150.
  153. Holmes DRJ, White HD, Pieper F, Ellis SG, Califf RM, Topol EJ. Effect of age on outcome with primary angioplasty versus thrombolysis J Am Coll Cardiol 1999;33:412-419.
  154. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trialGlobal Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation 1996;94:1826-1833.
  155. Jayes RLJ, Beshansky JR, D’Agostino RB, Selker HP. Do patients’ coronary risk factor reports predict acute cardiac ischemia in the emergency department?A multicenter study. J Clin Epidemiol 1992;45:621-626.
  156. Michos ED, Vasamreddy CR, Becker DM, et al. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis Am Heart J 2005;150:1276-1281.
  157. Tadros GM, McConnell TR, Wood GC, Costello JM, Iliadis EA. Clinical predictors of 30- day cardiac events in patients with acute coronary syndrome at a community hospital South Med J 2003;96:1113-1120.
  158. Nasir K, Michos ED, Rumberger JA, et al. Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history Circulation 2004;110:2150-2156.
  159. Mak KH, Moliterno DJ, Granger CB, et al. GUSTO-I Investigators Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarctionGlobal Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171-179.
  160. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making JAMA 2000;284:835- 842.
  161. Mehta RH, Califf RM, Garg J, et al. The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction Eur Heart J 2006;28:415-424.
  162. Nigam A, Wright RS, Allison TG, et al. Excess weight at time of presentation of myocardial infarction is associated with lower initial mortality risks but higher long-term risks including recurrent re-infarction and cardiac death Int J Cardiol 2006;110:153-159.
  163. Diercks DB, Roe MT, Mulgund J, et al. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative Am Heart J 2006;152:140-148.
  164. Rubinshtein R, Halon DA, Jaffe R, Shahla J, Lewis BS. Relation between obesity and severity of coronary artery disease in patients undergoing coronary angiography Am J Cardiol 2006;97:1277-1280.
  165. Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women N Engl J Med 2006;355:779-787.
  166. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old N Engl J Med 2006;355:763-778.
  167. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies Lancet 2006;368:666-678.
  168. Mittleman MA, Mintzer D, Maclure M, Tofler GH, Sherwood JB, Muller JE. Triggering of myocardial infarction by cocaine Circulation 1999;99:2737-2741.
  169. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 2004;291:2727-2733.
  170. Cohen M, Demers C, Gurfinkel EP, et al. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease N Engl J Med 1997;337:447-452.
  171. Pollack Jr. CV, Sites FD, Shofer FS, Sease KL, Hollander JE. Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population Acad Emerg Med 2006;23:13-18.
  172. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy Lancet 2001;358:1571- 1575.
  173. Boersma E, Pieper KS, Steyerberg EW, et al. The PURSUIT Investigators Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevationResults from an international trial of 9461 patients. Circulation 2000;101:2557-2567.
  174. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events Arch Intern Med 2003;163:2345-2353.
  175. Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes J Am Coll Cardiol 2005;46:906-919.
  176. Selker HP, Zalenski RJ, Antman EM, et al. An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: a report from a National Heart Attack Alert Program Working Group(published erratum appears in Ann Emerg Med 1997;29:310) Ann Emerg Med 1997;29:13-87.
  177. Savonitto S, Cohen MG, Politi A, et al. Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes Eur Heart J 2005;26:2106-2113.
  178. Chang WC, Kaul P, Fu Y, et al. Forecasting mortality: dynamic assessment of risk in ST- segment elevation acute myocardial infarction Eur Heart J 2006;27:419-426.
  179. Das M, Aronow WS, McClung JA, Belkin RN. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency Cardiol Rev 2006;14:14-17.
  180. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease JAMA 2006;296:1377-1384.
  181. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial Circulation 1999;100:1593-1601.
  182. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromesApplication of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002;23:223-229.
  183. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 2001;344:1879-1887.
  184. Zaacks SM, Liebson PR, Calvin JE, Parrillo JE, Klein LW. Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol 1999;33:107-118.
  185. Rouan GW, Lee TH, Cook EF, Brand DA, Weisberg MC, Goldman L. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study) Am J Cardiol 1989;64:1087-1092.
  186. Lee TH, Cook EF, Weisberg MC, Rouan GW, Brand DA, Goldman L. Impact of the availability of a prior electrocardiogram on the triage of the patient with acute chest pain J Gen Intern Med 1990;5:381-388.
  187. Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 1990s? Circulation 1993;88:750-763.
  188. Matetzky S, Freimark D, Feinberg MS, et al. Acute myocardial infarction with isolated ST- segment elevation in posterior chest leads V7-9: "hidden" ST-segment elevations revealing acute posterior infarction J Am Coll Cardiol 1999;34:748-753.
  189. Boden WE, Kleiger RE, Gibson RS, et al. Electrocardiographic evolution of posterior acute myocardial infarction: importance of early precordial ST-segment depression Am J Cardiol 1987;59:782-787.
  190. Zalenski RJ, Rydman RJ, Sloan EP, et al. Value of posterior and right ventricular leads in comparison to the standard 12-lead electrocardiogram in evaluation of ST-segment elevation in suspected acute myocardial infarction Am J Cardiol 1997;79:1579-1585.
  191. de Zwaan C, Bar FW, Janssen JH, et al. Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery Am Heart J 1989;117:657-665.
  192. Haines DE, Raabe DS, Gundel WD, Wackers FJ. Anatomic and prognostic significance of new T-wave inversion in unstable angina Am J Cardiol 1983;52:14-18.
  193. Renkin J, Wijns W, Ladha Z, Col J. Reversal of segmental hypokinesis by coronary angioplasty in patients with unstable angina, persistent T wave inversion, and left anterior descending coronary artery stenosisAdditional evidence for myocardial stunning in humans. Circulation 1990;82:913-921.
  194. McCarthy BD, Wong JB, Selker HP. Detecting acute cardiac ischemia in the emergency department: a review of the literature J Gen Intern Med 1990;5:365-373.
  195. Slater DK, Hlatky MA, Mark DB, Harrell FEJ, Pryor DB, Califf RM. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings Am J Cardiol 1987;60:766-770.
  196. Agarwal JB, Khaw K, Aurignac F, LoCurto A. Importance of posterior chest leads in patients with suspected myocardial infarction, but nondiagnostic, routine 12-lead electrocardiogram Am J Cardiol 1999;83:323-326.
  197. Zalenski RJ, Rydman RJ, Sloan EP, et al. ST segment elevation and the prediction of hospital life-threatening complications: the role of right ventricular and posterior leads J Electrocardiol 1998;3(Suppl): 164-171.
  198. Matetzky S, Freimark D, Chouraqui P, et al. Significance of ST segment elevations in posterior chest leads (V7 to V9) in patients with acute inferior myocardial infarction: application for thrombolytic therapy J Am Coll Cardiol 1998;31:506-511.
  199. Bayes de Luna A, Wagner G, Birnbaum Y, et al. A new terminology for left ventricular walls and location of myocardial infarcts that present Q wave based on the standard of cardiac magnetic resonance imaging: a statement for healthcare professionals from a committee appointed by the International Society for Holter and Noninvasive Electrocardiography Circulation 2006;114:1755-1760.
  200. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary StudyThrombolysis in Myocardial Ischemia. J Am Coll Cardiol 1997;30:133-140.
  201. Ohman EM, Armstrong PW, Christenson RH, et al. GUSTO IIA Investigators Cardiac troponin T levels for risk stratification in acute myocardial ischemia N Engl J Med 1996;335:1333- 1341.
  202. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes N Engl J Med 1996;335:1342-1349.
  203. Hyde TA, French JK, Wong CK, Straznicky IT, Whitlock RM, White HD. Four-year survival of patients with acute coronary syndromes without ST- segment elevation and prognostic significance of 0.5-mm ST-segment depression Am J Cardiol 1999;84:379-385.
  204. Lloyd-Jones DM, Camargo CAJ, Lapuerta P, Giugliano RP, O’Donnell CJ. Electrocardiographic and clinical predictors of acute myocardial infarction in patients with unstable angina pectoris Am J Cardiol 1998;81:1182-1186.
  205. Brush Jr. JE, Brand DA, Acampora D, Chalmer B, Wackers FJ. Use of the initial electrocardiogram to predict in-hospital complications of acute myocardial infarction N Engl J Med 1985;312:1137-1141.
  206. Fesmire FM, Percy RF, Wears RL, MacMath TL. Risk stratification according to the initial electrocardiogram in patients with suspected acute myocardial infarction Arch Intern Med 1989;849:1294-1297.
  207. Fesmire FM, Percy RF, Wears RL. Diagnostic and prognostic importance of comparing the initial to the previous electrocardiogram in patients admitted for suspected acute myocardial infarction South Med J 1991;84:841-846.
  208. Fesmire FM, Wharton DR, Calhoun FB. Instability of ST segments in the early stages of acute myocardial infarction in patients undergoing continuous 12-lead ECG monitoring Am J Emerg Med 1995;13:158-163.
  209. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain Ann Emerg Med 1998;31:3-11.
  210. Kudenchuk PJ, Maynard C, Cobb LA, et al. Utility of the prehospital electrocardiogram in diagnosing acute coronary syndromes: the Myocardial Infarction Triage and Intervention (MITI) project J Am Coll Cardiol 1998;32:17-27.
  211. Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome J Am Coll Cardiol 1989;13:1495-1502.
  212. Langer A, Freeman MR, Armstrong PW. Relation of angiographic detected intracoronary thrombus and silent myocardial ischemia in unstable angina pectoris Am J Cardiol 1990;66:1381- 1382.
  213. Fesmire FM. Delta CK-MB outperforms delta troponin I at 2 hours during the ED rule out of acute myocardial infarction Am J Emerg Med 2000;18:1-8.
  214. Hedges JR, Young GP, Henkel GF, Gibler WB, Green TR, Swanson JR. Serial ECGs are less accurate than serial CK-MB results for emergency department diagnosis of myocardial infarction Ann Emerg Med 1992;21:1445-1450.
  215. Fesmire FM, Hughes AD, Fody EP, et al. The Erlanger chest pain evaluation protocol: a one-year experience with serial 12-lead ECG monitoring, two-hour delta serum marker measurements, and selective nuclear stress testing to identify and exclude acute coronary syndromes Ann Emerg Med 2002;40:584-594.
  216. Patel DJ, Holdright DR, Knight CJ, et al. Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram Heart 1996;75:222-228.
  217. Patel DJ, Knight CJ, Holdright DR, et al. Long-term prognosis in unstable angina: the importance of early risk stratification using continuous ST segment monitoring Eur Heart J 1998;19:240-249.
  218. Hochman JS, Sleeper LA, Godfrey E, et al. The SHOCK Trial Study Group SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG-trial design Am Heart J 1999;137:313-321.
  219. Holmes Jr. DR, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation Circulation 1999;100:2067-2073.
  220. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction J Am Coll Cardiol 2000;36:959-969.
  221. Shapiro BP, Jaffe AS. Cardiac biomarkersIn: Murphy JG, Lloyd MA, editors. May Clinic Cardiology: Concise Textbook. 3rd edition. Rochester, MN: Informa Healthcare USA; 2007. pp. 773-780Mayo Clinic Scientific Press and New York, NY.
  222. Tsung SH. Several conditions causing elevation of serum CK-MB and CK-BB Am J Clin Pathol 1981;75:711-715.
  223. Christenson RH, Vaidya H, Landt Y, et al. Standardization of creatine kinase-MB (CK-MB) mass assays: the use of recombinant CK-MB as a reference material Clin Chem 1999;45:1414- 1423.
  224. Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Puschendorf B. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction Clin Chem 1995;41:1266-1272.
  225. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future J Am Coll Cardiol 2006;48:1-11.
  226. James SK, Lindahl B, Armstrong P, et al. A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes Int J Cardiol 2004;93:113-120.
  227. Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations Clin Chem 2004;50:327-332.
  228. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications J Am Coll Cardiol 2002;40:2065-2071.
  229. Roger VL, Killian JM, Weston SA, et al. Redefinition of myocardial infarction: prospective evaluation in the community Circulation 2006;114:790-797.
  230. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I N Engl J Med 1997;337:1648-1653.
  231. Galvani M, Ottani F, Ferrini D, et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina Circulation 1997;95:2053-2059.
  232. Lindahl B, Andren B, Ohlsson J, Venge P, Wallentin L, FRISK Study Group Risk stratification in unstable coronary artery disease: additive value of troponin T determinations and pre-discharge exercise tests Eur Heart J 1997;18:762-770.
  233. Heidenreich PA, Go A, Melsop KA, et al. Prediction of risk for patients with unstable angina Evid Rep Technol Assess 2000:1-3Summ.
  234. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction N Engl J Med 2002;346:2047-2052.
  235. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 2005;353:238-248.
  236. Dragu R, Behar S, Sandach A, et al. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction? Am J Cardiol 2006;97:1142-1145.
  237. Han JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients with non-ST- segment elevation acute coronary syndromes Am J Med 2006;119:248-254.
  238. Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS. Renal insufficiency and mortality from acute coronary syndromes Am Heart J 2004;147:623-629.
  239. Yan AT, Yan RT, Tan M, et al. Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes Can J Cardiol 2006;22:115-120.
  240. Wison S, Foo K, Cunningham J, et al. Renal function and risk stratification in acute coronary syndromes Am J Cardiol 2003;91:1051-1054.
  241. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators N Engl J Med 1999;340:1623-1629.
  242. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD, PRISM Study Investigators Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofibanPlatelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354:1757-1762.
  243. Lindahl B, Venge P, Wallentin L, Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection J Am Coll Cardiol 1997;29:43-48.
  244. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 2001;345:494-502.
  245. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial JAMA 2006;295:1531-1538.
  246. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study Lancet 1999;354:708-715.
  247. Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle- brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes J Am Coll Cardiol 2002;40:1044-1050.
  248. Marin MM, Teichman SL. Use of rapid serial sampling of creatine kinase MB for very early detection of myocardial infarction in patients with acute chest pain Am Heart J 1992;123:354-361.
  249. Young GP, Gibler WB, Hedges JR, et al. Serial creatine kinase-MB results are a sensitive indicator of acute myocardial infarction in chest pain patients with nondiagnostic electrocardiograms: the second Emergency Medicine Cardiac Research Group Study Acad Emerg Med 1997;4:869-877.
  250. Apple FS, Christenson RH, Valdes RJ, et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction Clin Chem 1999;45:199-205.
  251. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of + 1.6ng/ml Am Heart J 1998;136:237-244.
  252. Fesmire FM, Peterson ED, Roe MT, Wojcik JF. Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: a local quality improvement initiative Am J Emerg Med 2003;21:302-308.
  253. Lindahl B, Venge P, Wallentin L, The BIOMACS Study Group Early diagnosis and exclusion of acute myocardial infarction using biochemical monitoringBiochemicals Markers of Acute Coronary Syndromes. Coron Artery Dis 1995;6:321-328.
  254. Stork TV, Wu AH, Muller-Bardorff M, et al. North-Wurttemberg Infarction Study (NOWIS) Group Diagnostic and prognostic role of myoglobin in patients with suspected acute coronary syndrome Am J Cardiol 2000;86:1371-1374.
  255. McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I Circulation 2001;104:1483-1488.
  256. Ng SM, Krishnaswamy P, Morissey R, Clopton P, Fitzgerald R, Maisel AS. Ninety-minute accelerated critical pathway for chest pain evaluation Am J Cardiol 2001;88:611-617.
  257. Sallach SM, Nowak R, Hudson MP, et al. A change in serum myoglobin to detect acute myocardial infarction in patients with normal troponin I levels Am J Cardiol 2004;94:864-867.
  258. de Winter RJ, Lijmer JG, Koster RW, Hoek FJ, Sanders GT. Diagnostic accuracy of myoglobin concentration for the early diagnosis of acute myocardial infarction Ann Emerg Med 2000;35:113-120.
  259. Eggers KM, Oldgren J, Nordenskjold A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction Am Heart J 2004;148:574-581.
  260. Kontos MC, Anderson FP, Hanbury CM, Roberts CS, Miller WG, Jesse RL. Use of the combination of myoglobin and CK-MB mass for the rapid diagnosis of acute myocardial infarction Am J Emerg Med 1997;15:14-19.
  261. Hamm CW, Braunwald E. A classification of unstable angina revisited Circulation 2000;102:118-122.
  262. Rao SV, Ohman EM, Granger CB, et al. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes Am J Cardiol 2003;91:936-940.
  263. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide Circulation 2002;105:1760-1763.
  264. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18 J Am Coll Cardiol 2003;41:1264-1272.
  265. Roy D, Quiles J, Aldama G, et al. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T Int J Cardiol 2004;97:297-301.
  266. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department Am Heart J 2006;152:253-262.
  267. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non—ST-elevation acute coronary syndrome Circulation 2007;115:962-971.
  268. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease N Engl J Med 1987;317:1361-1365.
  269. Tataru MC, Heinrich J, Junker R, et al. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction Eur Heart J 1999;20:1493-1502.
  270. Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Coagulation activity and clinical outcome in unstable coronary artery disease Arterioscler Thromb Vasc Biol 2001;21:1059-1064.
  271. Eikelboom JW, Weitz JI, Budaj A, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes Eur Heart J 2002;23:1771-1779.
  272. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease Am J Cardiol 2001;88:230-235.
  273. Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug J Am Coll Cardiol 2005;46:638-645.
  274. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance J Am Coll Cardiol 2006;47:27-33.
  275. Oltrona L, Ardissino D, Merlini PA, Spinola A, Chiodo F, Pezzano A. C-reactive protein elevation and early outcome in patients with unstable angina pectoris Am J Cardiol 1997;80:1002- 1006.
  276. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudyThrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998;31:1460-1465.
  277. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy N Engl J Med 2005;352:20-28.
  278. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina Circulation 1996;94:874-877.
  279. Ghaisas NK, Shahi CN, Foley B, et al. Elevated levels of circulating soluble adhesion molecules in peripheral blood of patients with unstable angina Am J Cardiol 1997;80:617-619.
  280. Lund J, Qin QP, Ilva T, et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation Circulation 2003;108:1924-1926.
  281. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain N Engl J Med 2003;349:1595-1604.
  282. Galvani M, Ottani F, Oltrona L, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes Circulation 2004;110:128-134.
  283. de Lemos JA, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation 2002;106:2868-2870.
  284. Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes Am J Cardiol 2002;89:463- 465.
  285. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation J Am Coll Cardiol 2002;40:437-445.
  286. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy Circulation 2003;108:275-281.
  287. Cannon CP, O’Gara PT. Critical pathways for acute coronary syndromesIn: Cannon CP, editor. Management of Acute Coronary Syndromes. Totowa, NJ: Humana Press; 1999. pp. 611-627.
  288. Gibler WB, Runyon JP, Levy RC, et al. A rapid diagnostic and treatment center for patients with chest pain in the emergency department Ann Emerg Med 1995;25:1-8.
  289. Graff L, Joseph T, Andelman R, et al. American College of Emergency Physicians information paperChest pain units in emergency departments: a report from the Short-Term Observation Services Section. Am J Cardiol 1995;76:1036-1039.
  290. Brillman J, Mathers-Dunbar L, Graff L, et al. American College of Emergency Physicians Management of observation units Ann Emerg Med 1995;25:823-830.
  291. Graff LG, Dallara J, Ross MA, et al. Impact on the care of the emergency department chest pain patient from the chest pain evaluation registry (CHEPER) study Am J Cardiol 1997;80:563-
    568.
  292. Gomez MA, Anderson JL, Karagounis LA, Muhlestein JB, Mooers FB. An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO) J Am Coll Cardiol 1996;28:25-33.
  293. Newby LK, Mark DB. The chest-pain unit—ready for prime time(editorial)? N Engl J Med 1998;339:1930-1932.
  294. Kuntz KM, Fleischmann KE, Hunink MGM, Douglas PS. Cost-effectiveness of diagnostic strategies for patients with chest pain Ann Intern Med 1999;130:709-718.
  295. Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease Ann Intern Med 1999;130:719-728.
  296. Hendel RC, Patel MR, Kramer CM, et al. ACCF/ ACR/ SCCT/ SCMR/ ASNC/ NASCI/ SCAI/ SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology J Am Coll Cardiol 2006;48:1475-1497.
  297. Fuster V, Kim RJ. Frontiers in cardiovascular magnetic resonance Circulation 2005;112:135-144.
  298. Klem I, Heitner JF, Shah DJ, et al. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging J Am Coll Cardiol 2006;47:1630-1638.
  299. Raff GL, Gallagher MJ, O’Neill WW, Goldstein JA. Diagnostic accuracy of noninvasive coronary angiography using 64-slice spiral computed tomography J Am Coll Cardiol 2005;46:552-557.
  300. Mollet NR, Cademartiri F, van Mieghem CA, et al. High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography Circulation 2005;112:2318-2323.
  301. Fine JJ, Hopkins CB, Ruff N, Newton FC. Comparison of accuracy of 64-slice cardiovascular computed tomography with coronary angiography in patients with suspected coronary artery disease Am J Cardiol 2006;97:173-174.
  302. Armstrong PW. Stable ischemic syndromes In: Topol EJ, editor. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippincott-Raven; 1998. pp. 349-350.
  303. Taladafil package insert. Доступно на: http://pi.lilly.com/us/cialis-pi.pdf. Действительно на: August 10, 2006.
  304. Sildenafil package insert. Доступно на: http://pfizer.com/pfizer/download/uspi_viagra.pdf. Действительно на August 10, 2006.
  305. Cheitlin MD, Hutter AMJ, Brindis RG, et al. American College of Cardiology/American Heart Association ACC/AHA expert consensus document: use of sildenafil (Viagra) in patients with cardiovascular disease J Am Coll Cardiol 1999;33:273-282.
  306. Vardenafil                               package                              insert.                             Доступно                               на: http://www.univgraph.com/bayer/inserts/levitra.pdf. Действительно на August 10, 2006.
  307. Ссылка удалена
  308. Physicians’ Desk Reference. 53rd edition. Mountvale, NJ: Medical Economic Co, Inc; 1999. pp. 1331.
  309. Esposito GA, Dunham G, Granger BB, Tudor GE, Granger CB. Converting i.v. nitroglycerin therapy to nitroglycerin ointment therapy: a comparison of two methods Am J Crit Care 1998;7:123-130.
  310. Dellborg M, Gustafsson G, Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris Eur J Clin Pharmacol 1991;41:5-9.
  311. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials Lancet 1988;1:1088-1092.
  312. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction Lancet 1995;345:669-685.
  313. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction Lancet 1994;343:1115-1122.
  314. Figueras J, Lidon R, Cortadellas J. Rebound myocardial ischaemia following abrupt interruption of intravenous nitroglycerin infusion in patients with unstable angina at rest Eur Heart J 1991;12:405-411.
  315. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative Am Heart J 2005;149:1043-1049.
  316. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarctionResults of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83:422-437.
  317. Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy J Am Coll Cardiol 1993;22:407-416.
  318. Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experienceGlobal Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998;32:634-640.
  319. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 2005;366:1622-1632.
  320. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 2003;362:7-13.
  321. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-1689.
  322. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 2005;366:895-906.
  323. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left- ventricular dysfunction: the CAPRICORN randomised trial Lancet 2001;537:1385-1390.
  324. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart diseaseII. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-2263.
  325. Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport trials J Interv Cardiol 2003;16:299-305.
  326. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology J Am Coll Cardiol 2006;47:2343-2355.
  327. White HD. Unstable anginaIn: Topol EJ, editor. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippincott-Raven; 1998. pp. 379.
  328. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease Circulation 1995;92:1326-1331.
  329. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT) Am J Cardiol 1987;60:18A-25A.
  330. Beevers DG, Sleight P. Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk? BMJ 1996;312:1143-1145.
  331. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q- wave myocardial infarctionResults of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-429.
  332. Hansen JF, Hagerup L, Sigurd B, et al. Danish Verapamil Infarction Trial (DAVIT) Study Group Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone Am J Cardiol 1997;79:738-741.
  333. Opie LH. Pharmacologic options for treatment of ischemic heart diseaseIn: Smith TW, editor. Cardiovascular Therapeutics: A Companion to Braunwald’s Heart Disease. Philadelphia, PA: W.B. Saunders; 1996. pp. 22-57.
  334. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials Clin C ardiol 1998;21:633-641.
  335. The Danish Study Group on Verapamil in Myocardial Infarction Verapamil in acute myocardial infarction Eur Heart J 1984;5:516-528.
  336. Boden WE, Krone RJ, Kleiger RE, et al. The Multicenter Diltiazem Post-Infarction Trial Research Group Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction Am J Cardiol 1991;67:335-342.
  337. Tijssen JG, Lubsen J. Nifedipine and metoprolol in unstable angina: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT) J Cardiovasc Pharmacol 1987;10(Suppl 2):S15-S24.
  338. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview BMJ 1989;299:1187-1192.
  339. Hansen JF, Tingsted L, Rasmussen V, Madsen JK, Jespersen CM. Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction Am J Cardiol 1996;77:16D-21D.
  340. Theroux P, Gregoire J, Chin C, Pelletier G, de Guise P, Juneau M. Intravenous diltiazem in acute myocardial infarction: diltiazem as adjunctive therapy to activase (DATA) trial J Am Coll Cardiol 1998;32:620-628.
  341. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions Lancet 1992;340:1173-1178.
  342. Rutherford JD, Pfeffer MA, Moye LA, et al. SAVE Investigators Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement trial Circulation 1994;90:1731-1738.
  343. ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials Circulation 1998;97:2202-2212.
  344. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P, Trace Study Group Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction J Am Coll Cardiol 1999;34:83-89.
  345. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients(published correction appears in N Engl J Med 2000;342:748) N Engl J Med 2000;342:145-153.
  346. Buch P, Rasmussen S, Abildstrom SZ, Kober L, Carlsen J, Torp-Pedersen C. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years Eur Heart J 2005;26:145-152.
  347. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin- converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review Lancet 2002;360:1037-1043.
  348. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 2003;349:1893-1906.
  349. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 2003;362:759-766.
  350. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003;348:1309-1321.
  351. Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 1999;341:709-717.
  352. TenVaarwerk IA, Jessurun GA, DeJongste MJ, et al. The Working Group on Neurocardiology Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris Heart 1999;82:82-88.
  353. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes J Am Coll Cardiol 1999;33:1833-1840.
  354. Conti CR. EECP-enhanced external counterpulsation J Am Coll Cardiol 1999;33:1841- 1842.
  355. Hautvast RW, DeJongste MJ, Staal MJ, van Gilst WH, Lie KI. Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study Am Heart J 1998;136:1114-1120.
  356. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandilCESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J 1999;20:51-57.
  357. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina J Am Coll Cardiol 2004;43:1375-1382.
  358. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 2004;110:904-910.
  359. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial Am Heart J 2006;151:1186-1189.
  360. 357a. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 2007;297:1775-1783.
  361. Stone GW, Ohman EM, Miller MF, et al. Contemporary utilization and outcomes of intra- aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry J Am Coll Cardiol 2003;41:1940-1945.
  362. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo- oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?Meta-analysis of randomised trials. BMJ 2006;332:1302-1308.]
  363. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 2006;296:1633-1644.
  364. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction Circulation 2006;113:2906-2913.
  365. Gibson CM, Braunwald B. Association of treatment with non-steroidal anti-inflammatory agents (NSAIDS) on study entry with 30 day adverse outcomes among ST elevation MI (STEMI) patients treated with fibrinolytic agentAn EXTRACT-TIMI 25 ANALYSIS (abstr). Circulation 2006;114(Suppl II):697.
  366. Antiplatelet Trialists’ Collaboration Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients(published erratum appears in BMJ 1994;308:1540) BMJ 1994;308:81-106.
  367. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men (published erratum appears in N Engl J Med 1997;337:356) N Engl J Med 1997;336:973-979.
  368. Lewis HDJ, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study N Engl J Med 1983;309:396-403.
  369. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial N Engl J Med 1985;313:1369-1375.
  370. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina N Engl J Med 1988;319:1105-1111.
  371. The RISC Group Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease Lancet 1990;336:827- 830.
  372. Cohen M, Adams PC, Parry G, et al. Antithrombotic Therapy in Acute Coronary Syndromes Research Group Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial Circulation 1994;89:81-88.
  373. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia J Am Coll Cardiol 1995;26:313-318.
  374. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group Low- molecular-weight heparin during instability in coronary artery disease Lancet 1996;347:561-568.
  375. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study(published erratum appears in Lancet 1997;350:744) Lancet 1997;349:1429-1435.
  376. The PARAGON Investigators International, randomized, controlled trial of lamifiban (a plateletglycoprotein IIb/IIIa inhibitor), heparin, or both in unstable anginaPlatelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998;97:2386-2395.
  377. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina N Engl J Med 1998;338:1498-1505.
  378. Antithrombotics Trialists’ Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002;324:71-86.
  379. Plavix (clopidogrel) package insert. New York, NY: Sanofi-Synthelabo, 2002. Доступно на: http ://products.sanofi -aventi s.us/plavix/plavix. html.
  380. Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography J Pharm Biomed Anal 1999;21:383-392.
  381. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis J Am Coll Cardiol 2005;45:456-459.
  382. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 2004;364:1519-1521.
  383. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry Circulation 2006;113:2803-2809.
  384. New Information for Healthcare Professionals Concomitant Use of Ibuprofen and Aspirin. Доступно на: http://www.fda.gov/cder/drug/InfoSheets/HCP/ibuprofen_aspirinHCP.htm. Действительно на January 8, 2007.
  385. Song KH, Fedyk R, Hoover R. Interaction of ACE inhibitors and aspirin in patients with congestive heart failure Ann Pharmacother 1999;33:375-377.
  386. Schror K. The basic pharmacology of ticlopidine and clopidogrel Platelets 1993;4:252-261.
  387. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use N Engl J Med 2002;346:2033-2038.
  388. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding N Engl J Med 2005;532:238-244.
  389. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding BMJ 2005;330:568.
  390. Balsano F, Rizzon P, Violi F, et al. The Studio della Ticlopidina nell’Angina Instabile Group Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial Circulation 1990;82:17-26.
  391. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidinePrevention, recognition and management. Drug Saf 1998;19:89-98.
  392. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996;348:1329-1339.
  393. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel N Engl J Med 2000;342:1773-1777.
  394. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial Circulation 2005;112:2946-2950.
  395. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 2006;48:931-938.
  396. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di SG. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Circulation 2005;111:2099-2106.
  397. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery J Am Coll Cardiol 2006;48:281-286.
  398. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents Circulation 2000;101:590-593.
  399. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, CLASSICS Investigators Double­blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 2000;102:624-629.
  400. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention: the PCI- CURE study Lancet 2001;358:527-533.
  401. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone Ann Intern Med 2005;142:251-259.
  402. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings J Am Coll Cardiol 2006;47:2108-2111.
  403. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications Circulation 2007;115:1051-1058.
  404. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 2006;48:2584-2591.
  405. Food and Drug Administration. Circulatory System Devices Advisory Panel transcript for December     8,            2006                meeting.              Доступно          на: http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4253t2.rtf. Действительно на February 2007.
  406. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up Am J Cardiol 2006;98:352-356.
  407. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials Am J Med 2006;119:1056-1061.
  408. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 2007;356:989-997.
  409. 404a. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel- eluting coronary stents N Engl J Med 2007;356:998-1008.
    404b. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 2007;356:1020-1029.
    404c. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 2007;356:1030-1039.
    404d. Maisel WH. Unanswered questions—drug-eluting stents and the risk of late thrombosis N Engl J Med 2007;356:981-984.
    404e. Farb A, Boam AB. Stent thrombosis redux—the FDA perspective N Engl J Med 2007;356:984-987.
    404f. Ellis SG, Colombo A, Grube E, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V and VI meta-analysis of 3,445 patients followed for up to 3 years J Am Coll Cardiol 2007;49:1043-1051.
  410. Steinhubl SR, Berger PB, Mann III JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 2002;288:2411-2420.
  411. Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal timing for the initiation of pre­treatment with 300 mg clopidogrel before percutaneous coronary intervention J Am Coll Cardiol 2006;47:939-943.
  412. van der Heijden DJ, Westendorp IC, Riezebos RK, et al. Lack of efficacy of clopidogrel pre­treatment in the prevention of myocardial damage after elective stent implantation J Am Coll Cardiol 2004;44:20-24.
  413. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial Circulation 2004;110:1202-1208.
  414. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease N Engl J Med 2002;346:1800-1806.
  415. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 2002;23:1809-1840.
  416. Grines C, Bonow RO, Casey D, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stentsA science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation from the American College of Physicians. Circulation 2007;115:813-818.
  417. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis Eur Heart J 2006;27:2784-2814.
  418. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes Circulation 2003;107:966-972.
  419. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 2006;354:1706-1717.
  420. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004;78:1536-1541.
  421. Ссылка удалена.
  422. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans Circulation 2000;101:2823-2828.
  423. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin Arterioscler Thromb Vasc Biol 2000;20:2316-2321.
  424. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 2005;45:246-251.
  425. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 2004; 109:3171-3175.
  426. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story Circulation 2004;109:3064-3067.
  427. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 2005;45:1392-1396.
  428. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high- risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 2004;292:45-54.
  429. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 2006;354:1464-1476.
  430. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes N Engl J Med 2006;355:2203-2216.
  431. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 2003;289:853-863.
  432. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience J Am Coll Cardiol 2005;46:1986-1995.
  433. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials Ann Intern Med 2006;145:62-69.
  434. D’Agostino Sr. RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues—the encounters of academic consultants in statistics Stat Med 2003;22:169-186.
  435. Hirsh J. Heparin N Engl J Med 1991;324:1565-1574.
  436. Weitz JI. Low-molecular-weight heparins(published erratum appears in N Engl J Med 1997;337:1567) N Engl J Med 1997;337:688-698.
  437. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin Biochemistry 1986;25:4622-4628.
  438. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 2006;295:1519-1530.
  439. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 2006;354:1477-1488.
  440. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome Lancet 1981;1:1225-1228.
  441. Williams DO, Kirby MG, McPherson K, Phear DN. Anticoagulant treatment of unstable angina Br J Clin Pract 1986;40:114-116.
  442. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina Circulation 1993;88:2045- 2048.
  443. Neri SG, Gensini GF, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina(published erratum appears in Lancet 1990;335:868) Lancet 1990;335:615-618.
  444. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina J Am Coll Cardiol 1994;24:39-45.
  445. Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non- Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group) Am J Cardiol 1990;66:1287-1292.
  446. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable anginaA meta-analysis. JAMA 1996;276:811-815.
  447. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin N Engl J Med 1992;327:141-145.
  448. Serruys PW, Herrman JP, Simon R, et al. Helvetica Investigators A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty N Engl J Med 1995;333:757- 763.
  449. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes N Engl J Med 1996;335:775-782.
  450. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial Circulation 1996;93:870-878.
  451. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes Circulation 1995;91:1929-1935.
  452. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low- molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety Chest 1998;114:489S-510S.
  453. Hassan WM, Flaker GC, Feutz C, Petroski GF, Smith D. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial J Thromb Thrombolysis 1995;2:245-249.
  454. Becker RC, Ball SP, Eisenberg P, et al. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease: Antithrombotic Therapy Consortium Investigators Am Heart J 1999;137:59-71.
  455. Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin use in acute coronary syndromes Am Heart J 1999;138:313-318.
  456. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 2004;126:188S-203S.
  457. Hochman JS, Wali AU, Barvila D, et al. A new regimen for heparin use in acute coronary syndromes Am Heart J 1999;138:313-318.
  458. Oliveira GB, Anstrom KJ, Honeycutt EF, et al. Intravenous unfractionated heparin, patient profile, and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH Registry(abstr) Eur Heart J 2005:725.
  459. Oliveira GB, Anstrom KJ, Honeycutt EF, et al. Prolonged heparin exposure, development of thrombocytopenia, use of GP IIb/IIIa inhibitors, and history of renal dysfunction predict moderate or severe bleeding: a report from the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry(abstr) J Am Coll Cardiol 2006:251A.
  460. Ohman EM, Granger CG, Rice L, et al. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease J Thromb Thrombolysis 2005;19:11-19.
  461. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 1995;332:1330- 1335.
  462. Warkentin TE, Greinacher A. Clinical picture of heparin-induced thrombocytopenia Heparin-Induced Thrombocytopenia. New York, NY: Marcel Kedder; 2004. pp. 53-106.
  463. Heparin                                package                               insert.                               Доступно                                на: http://www.baxter.com/products/anesthesia/anesthetic_pharmaceuticals/downloads/heparin.pdf. Действительно на January 8, 2007.
  464. Smythe MA, Stephens JL, Mattson JC. Delayed-onset heparin-induced thrombocytopenia Ann Emerg Med 2005;45:417-419.
  465. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis Ann Intern Med 2001;135:502-506.
  466. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris Circulation 2001;103:658-663.
  467. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery diseaseFragmin in unstable coronary artery disease study (FRIC). (published erratum appears in Circulation 1998;97:413) Circulation 1997;96:61-68.
  468. The F.R.A.X.I.S. Study Group Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome) Eur Heart J 1999;20:1553-1562.
  469. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II studyThe Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-477.
  470. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST- segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide Circulation 2003;107:238-244.
  471. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial JAMA 2004;292:55-64.
  472. Michalis LK, Katsouras CS, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST- segment elevation acute coronary syndromes: the EVET trial Am Heart J 2003;146:304-310.
  473. Antman EM. Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on Am Heart J 2003;146:191-193.
  474. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor Circulation 1998;97:251-256.
  475. Mahaffey KW, Ferguson JJ. Exploring the role of enoxaparin in the management of high- risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial Am Heart J 2005;149:S81-S90.
  476. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trialEfficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation 1998;97:1702-1707.
  477. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study Lancet 1999;354:701-707.
  478. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes Circulation 1994;90:1631-1637.
  479. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial Circulation 1996;94:911-921.
  480. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial Circulation 1994;90:1624-1630.
  481. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study Circulation 1997;96:769-777.
  482. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial Lancet 1999;353:429-438.
  483. Roe MT, Granger CB, Puma JA, et al. Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention Am J Cardiol 2001;88:1403-1406.
  484. Argatroban                              package                             insert.                             Доступно                               на: http://us.gsk.com/products/assets/us_argatroban.pdf. Действительно на August 10, 2006.
  485. The Direct Thrombin Inhibitor Trialists’ Collaborative Group Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data Lancet 2002;359:294-302.
  486. Antman EM. Should bivalirudin replace heparin during percutaneous coronary interventions? JAMA 2003;289:903-905.
  487. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial JAMA 2004;292:696-703.
  488. 482a. Stone G, Bertrand M, Moses J, et al. Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromesThe ACUITY Timing Trial. JAMA 2007;297:591-602.
    482b. Mahaffey K, Harrington R. Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes JAMA 2007;297:636-639.
    482c. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial Lancet 2007;369:907-919. 482d. Waksman R. ACUITY-PCI: one drug does not fit all Lancet 2007;369:881-882.
  489. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial Lancet 2001;358:1855-1863.
  490. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST- Segment elevation acute coronary syndromes: a systematic overview JAMA 2004;292:89-96.
  491. Ссылка удалена.
  492. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 2006;114:774-782.
  493. Williams MJ, Morison IM, Parker JH, Stewart RA. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study J Am Coll Cardiol 1997;30:364-369.
  494. Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results Circulation 1998;98:1064- 1070.
  495. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis JAMA 1999;282:2058-2067.
  496. Coumadin Aspirin Reinfarction Study (CARS) Investigators Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction Lancet 1997;350:389-396.
  497. Fiore LD, Ezekowitz, MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study Circulation 2002;105:557-563.
  498. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial Lancet 2002;360:109-113.
  499. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction N Engl J Med 2002;347:969-974.
  500. Kushner FG, Antman EM. Oral anticoagulation for atrial fibrillation after ST-elevation myocardial infarction: new evidence to guide clinical practice Circulation 2005;112:3212-3214.
  501. Stenestrand U, Lindback J, Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) Circulation 2005;112:3225-3231.
  502. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine N Engl J Med 1995;332:1553-1559.
  503. Coller BS. Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy [editorial] (corrected and republished in Circulation 1998;97:5—9) Circulation 1997;96:3828-3832.
  504. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers Lancet 1999;353:227-231.
  505. Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab Am Heart J 1999; 138:S1-S5.
  506. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins Circulation 1998;98:1085-1091.
  507. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide Am J Cardiol 1997;80:11B-20B.
  508. Kleiman NS. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists Coron Artery Dis 1998;9:603-616.
  509. Lynch JJJ, Cook JJ, Sitko GR, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther 1995;272:20-32.
  510. Theroux P. Tirofiban Drugs Today (Barc) 1999;35:59-73.
  511. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors Blood 1998;92:3240-3249.
  512. The SYMPHONY Investigators Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trialSibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000;355:337-345.
  513. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial Circulation 2000;102:149-156.
  514. O’Neill WW, Serruys P, Knudtson M, et al. EXCITE Trial Investigators Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularizationEvaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000;342:1316-1324.
  515. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease Circulation 2003;108:399-406.
  516. The EPIC Investigation Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 1994;330:956-961.
  517. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 1997;336:1689-1696.
  518. The EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockadeEvaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
  519. The Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON)-B Investigators Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes Circulation 2002;105:316-321.
  520. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV- ACS randomised trial Lancet 2001;357:1915-1924.
  521. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 2001;344:1888-1894.
  522. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions Am J Cardiol 2002;89:647-650.
  523. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-IIIntegrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-1428.
  524. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplastyRandomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-1453.
  525. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Lancet 2000;356:2037-2044.
  526. Gratsianskii NA. [Do low risk patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel need abciximab infusion? Results of ISAR-REACT study] Kardiologiia 2004;44:80-81.
  527. Mukherjee D, Mahaffey KW, Moliterno DJ, et al. Promise of combined low-molecular- weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B) Am Heart J 2002;144:995-1002.
  528. Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/angioplasty in evolving non-ST segment elevation myocardial infarction: an open multicenter randomized trialThe VINO Study. Eur Heart J 2002;23:230-238.
  529. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention Circulation 1999;100:2045-2048.
  530. Ссылка удалена.
  531. Morrow DA, Sabatine MS, Antman EM, et al. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS) Am J Cardiol 2004;94:774-776.
  532. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 2002;359:189-198.
  533. Berkowitz SD, Sane DC, Sigmon KN, et al. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization J Am Coll Cardiol 1998;32:311-319.
  534. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndromeThe platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999;99:2892-2900.
  535. Cohen M, Theroux P, Borzak S, et al. ACUTE II Investigators Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II studyThe Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-477.
  536. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither BMJ 1998;316:1337-1343.
  537. Franzosi MG, Santoro E, De Vita C, et al. The GISSI Investigators Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto-1 study Circulation 1998;98:2659-2665. 531a. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group Indications for fibrinolytic therapy in suspended acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients Lancet 1994;343:311-322.
  538. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes N Engl J Med 2005;353:1095-1104.]
  539. McCullough PA, O’Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapyResults of the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol 1998;32:596-605.
  540. Boden WE, O’Rourke RA, Crawford MH, et al. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators Outcomes in patients with acute non-Q- wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy(published erratum appears in N Engl J Med 1998;339:1091) N Engl J Med 1998;338:1785-1792.]
  541. RITA-2 Trial Participants Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial Lancet 1997;350:461-468.
  542. Peterson ED, Shaw LJ, Califf RM. Risk stratification after myocardial infarction Ann Intern Med 1997;126:561-582.
  543. Luchi RJ, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris: results of a Veterans Administration Cooperative Study N Engl J Med 1987;316:977-984.
  544. Takaro T, Hultgren H, Lipton MJ, et al. The VA cooperative randomized study of surgery for coronary arterial occlusive disease: IISubgroup with significant left main lesions. Circulation 1976;54(Suppl 3):107-117.
  545. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxparin for unstable angina/non-Q-wave myocardial infarction: TIMI11B-ESSENCE meta-analysis Circulation 1999;100:1602-1608.
  546. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial JAMA 2003;290:1593-1599.
  547. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Percutaneous Transluminal Coronary Angioplasty) Circulation 2001;103:3019-3041.
  548. Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature Am J Cardiol 2004;93:830-835.
  549. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials JAMA 2005;293:2908-2917.
  550. Biondi-Zoccai GG, Abbate A, Agostoni P, et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression Am Heart J 2005;149:504-511.
  551. Cannon CP. Revascularisation for everyone? Eur Heart J 2004;25:1471-1472.
  552. 545a. Hirsch A, Windhausen F, Tijssen JGP, Verheugt FWA, Hein Cornel J, de Winter RJ, Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) Investigators Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non—ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study Lancet 2007;369:827-835.
    545b. Non—ST-elevation acute coronary syndromes (comment) Lancet 2007;369:801-3.
  553. Fox KA, Poole-Wilson P, Clayton TC, et al. 5—year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial Lancet 2005;366:914-920.
  554. 546b. Boden WE, O’Rourke RA, Teo KK, et al. COURAGE Trial Research Group Optimal medical therapy with or without PCI for stable coronary disease (published comment appears in N Engl J Med 2007;356:1572—4) N Engl J Med 2007;356:1503-1516.
  555. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes a meta-analysis of contemporary randomized clinical trials J Am Coll Cardiol 2006;48:1319-1325.
  556. Hoenig MR, Doust JA, Aroney CN, Scott IA. Early invasive versus conservative strategies for unstable angina and non-ST-elevation myocardial infarction in the stent era Cochrane Database Syst Rev 2006;3CD004815.
  557. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E, FRISC II Investigators Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary- artery disease: the FRISC II invasive randomised trialFast Revascularisation during Instability in Coronary artery disease. Lancet 2000;356:9-16.
  558. Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E, Wallentin L. 5—year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study Lancet 2006;368:998-1004.
  559. Greenbaum AB, Harrington RA, Hudson MP, et al. PURSUIT Investigators Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes J Am Coll Cardiol 2001;37:492-498.
  560. Lagerqvist B, Safstrom K, Stahle E, Wallentin L, Swahn E, FRISC II Study Group Investigators Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? J Am Coll Cardiol 2001;38:41-48.]
  561. Mueller C, Neumann FJ, Roskamm H, et al. Women do have an improved long-term outcome after non-ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention: a prospective study in 1,450 consecutive patients J Am Coll Cardiol 2002;40:245-250.
  562. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J 2004;25:1641-1650.
  563. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery) Circulation 2004;110:e340-e347.
  564. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI)DANish trial in Acute Myocardial Infarction. Circulation 1997;96:748-755.
  565. Pepine CJ, Geller NL, Knatterud GL, et al. The Asymptomatic Cardiac Ischemia Pilot (ACIP) study: design of a randomized clinical trial, baseline data and implications for a long- term outcome trial(published erratum appears in J Am Coll Cardiol 1995;26:842) J Am Coll Cardiol 1994;24:1-10.
  566. Knatterud GL, Bourassa MG, Pepine CJ, et al. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12—week results of the Asymptomatic Cardiac
  567. Ischemia Pilot (ACIP) study(published erratum appears in J Am Coll Cardiol 1995;26:842) J Am Coll Cardiol 1994;24:11-20.
  568. 558a. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial JAMA 2007;297:1985-1991.
  569. Yusuf S, Flather M, Pogue J, et al. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation Lancet 1998;352:507-514.
  570. Ссылка удалена.
  571. Stone PH, Thompson B, Zaret BL, et al. Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction: a TIMI IIIB database study Eur Heart J 1999;20:1084-1093.
  572. Ссылка удалена.
  573. Bugiardini R, Pozzati A, Borghi A, et al. Angiographic morphology in unstable angina and its relation to transient myocardial ischemia and hospital outcome Am J Cardiol 1991;67:460-464.
  574. Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial) Am J Cardiol 1994;74:531-537.
  575. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes JAMA 2002;288:3124-3129.
  576. Albertsson P, Emanuelsson H, Karlsson T, et al. Morbidity and use of medical resources in patients with chest pain and normal or near-normal coronary arteries Am J Cardiol 1997;79:299- 304.
  577. Potts SG, Bass CM. Psychosocial outcome and use of medical resources in patients with chest pain and normal or near-normal coronary arteries: a long-term follow-up study Q J Med 1993;86:583-593.
  578. Cantor WJ, Mahaffey KW, Huang Z, et al. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal Catheter Cardiovasc Interv 2006;69:73-83.
  579. Miltenburg-van Zijl AJ, Simoons ML, Veerhoek RJ, Bossuyt PM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris J Am Coll Cardiol 1995;25:1286-1292.
  580. Nyman I, Areskog M, Areskog NH, Swahn E, Wallentin L, The RISC Study Group Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease J Intern Med 1993;134:293-301.
  581. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography) Circulation 2003;108:1146-1162.
  582. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging) Circulation 2003;108:1404-1418.
  583. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines) Circulation 2002;106:1883-1892.
  584. Kligfield P, Lauer MS. Exercise electrocardiogram testing: beyond the ST segment Circulation 2006;114:2070-2082.
  585. Mark DB, Shaw L, Harrell FEJ, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease N Engl J Med 1991;325:849-853.
  586. O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for clinical use of cardiac radionuclide imaging, December 1986A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on Nuclear Imaging). J Am Coll Cardiol 1986;8:1471-1483.
  587. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography)Developed in collaboration with the American Society of Echocardiography. Circulation 1997;95:1686-1744.
  588. Manning WJ. Stress echocardiography in the diagnosis and prognosis of coronary heart disease. Доступно на: http://patients.uptodate.com/topic.asp?file=chd/55189. Accessed January 11, 2007.
  589. Nyman I, Larsson H, Areskog M, Areskog NH, Wallentin L, RISC Study Group The predictive value of silent ischemia at an exercise test before discharge after an episode of unstable coronary artery disease Am Heart J 1992;123:324-331.
  590. Starling MR, Crawford MH, Kennedy GT, O’Rourke RA. Treadmill exercise tests predischarge and six weeks post-myocardial infarction to detect abnormalities of known prognostic value Ann Intern Med 1981;94:721-727.
  591. Marwick TH, Anderson T, Williams MJ, et al. Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women J Am Coll Cardiol 1995;26:335-341.
  592. Larsson H, Areskog M, Areskog NH, et al. Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction? Int J Card Imaging 1991;7:7-14.
  593. Goyal A, Samaha FF, Boden WE, Wade MJ, Kimmel SE. Stress test criteria used in the conservative arm of the FRISC-II trial underdetects surgical coronary artery disease when applied to patients in the VANQWISH trial J Am Coll Cardiol 2002;39:1601-1607.
  594. Jones RH, Kesler K, Phillips HR, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease J Thorac Cardiovasc Surg 1996;111:1013-1025.
  595. Hannan EL, Racz MJ, McCallister BD, et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty J Am Coll Cardiol 1999;33:63-72.
  596. Rahimtoola SH, Nunley D, Grunkemeier G, Tepley J, Lambert L, Starr A. Ten-year survival after coronary bypass surgery for unstable angina N Engl J Med 1983;308:676-681.
  597. Levin TN, Holloway S, Feldman T. Acute and late clinical outcome after rotational atherectomy for complex coronary disease Cathet Cardiovasc Diagn 1998;45:122-130.
  598. Rosenblum J, Pensabene JF, Kramer B. The transluminal extraction catheter device: atherectomy and removal of an intracoronary thrombus J Inv Cardiol 1991:310-312.
  599. Williams DO, Braunwald E, Thompson B, Sharaf BL, Buller CE, Knatterud GL. Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction: observations from the TIMI IIIB Trial Circulation 1996;94:2749-2755.
  600. Moreyra AE, Palmeri ST, Wilson AC, Kulkarni A, Kulkarni R. Coronary angioplasty in unstable angina: contemporary experience Can J Cardiol 1995;11:385-390.
  601. Stammen F, De Scheerder I, Glazier JJ, et al. Immediate and follow-up results of the conservative coronary angioplasty strategy for unstable angina pectoris Am J Cardiol 1992;69:1533-1537.
  602. Perry RA, Seth A, Hunt A, Shiu MF. Coronary angioplasty in unstable angina and stable angina: a comparison of success and complications Br Heart J 1988;60:367-372.
  603. Safian RD, Snyder LD, Synder BA, et al. Usefulness of percutaneous transluminal coronary angioplasty for unstable angina pectoris after non-Q-wave acute myocardial infarction Am J Cardiol 1987;59:263-266.
  604. Kamp O, Beatt KJ, De Feyter PJ, et al. Short-, medium-, and long-term follow-up after percutaneous transluminal coronary angioplasty for stable and unstable angina pectoris Am Heart J 1989;117:991-996.
  605. Cairns J, Theroux P, Armstrong P, et al. Unstable angina—report from a Canadian expert roundtable Can J Cardiol 1996;12:1279-1292.
  606. Khan MM, Ellis SG, Aguirre FV, et al. EPIC Investigators Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trialEvaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1998;31:31-36.
  607. Malosky SA, Hirshfeld JWJ, Herrmann HC. Comparison of results of intracoronary stenting in patients with unstable vs. stable angina Cathet Cardiovasc Diagn 1994;31:95-101.
  608. Marzocchi A, Piovaccari G, Marrozzini C, et al. Results of coronary stenting for unstable versus stable angina pectoris Am J Cardiol 1997;79:1314-1318.
  609. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month Circulation 1998;98:104-111.
  610. Ссылка удалена.
  611. Kandzari DE, Roe MT, Ohman EM, et al. Frequency, predictors, and outcomes of drug- eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes Am J Cardiol 2005;96:750-755.
  612. Hochman JS, Lamas GA, Knatterud GL, et al. Design and methodology of the Occluded Artery Trial (OAT) Am Heart J 2005;150:627-642.
  613. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction N Engl J Med 2006;355:2395-2407.
  614. Topol EJ, Califf RM, Weisman HF, et al. The EPIC Investigators Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 1994;343:881-886.
  615. Topol EJ, Ferguson JJ, Weisman HF, et al. EPIC Investigator Group Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary interventionEvaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-484.
  616. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease Circulation 1998;98:2829-2835.
  617. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel N Engl J Med 2004;350:232-238.
  618. Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery Lancet 1995;346:1184-1189.
  619. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial JAMA 1997;277:715- 721.
  620. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease(published erratum appears in N Engl J Med 1997;336:147) N Engl J Med 1996;335:217-225.
  621. The BARI Investigators Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status J Am Coll Cardiol 2000;35:1122-1129.
  622. CABRI Trial Participants First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation) Lancet 1995;346:1179-1184.
  623. Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease J Am Coll Cardiol 1998;31:10-19.
  624. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation N Engl J Med 2005;352:2174-2183.
  625. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 1999;99:633-640.
  626. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes JAMA 2000;284:1549-1558.
  627. Ferguson Jr. TB, Hammill BG, Peterson ED, DeLong ER, Grover FL, Society of Thoracic Surgeons A decade of change—risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990—1999: a report from the STS National Database Committee and the Duke Clinical Research Institute Ann Thorac Surg 2002;73:480-489.
  628. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trialInvestigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol 2001;38:143-149.
  629. Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials J Thorac Cardiovasc Surg 2005;130:512-519.
  630. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease N Engl J Med 2001;344:1117-1124.
  631. Rodriguez A, Bernardi V, Navia J, et al. ERACI II Investigators Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results J Am Coll Cardiol 2001;37:51-58.
  632. The SoS Investigators Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial Lancet 2002;360:965-970.
  633. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS- II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results J Am Coll Cardiol 2004;43:1743-1751.
  634. Legrand VM, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease Circulation 2004;109:1114-1120.
  635. Khan NE, De SA, Mister R, et al. A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery N Engl J Med 2004;350:21-28.
  636. Camenzind E. Safety of drug-eluting stents: insights from meta analysis. Hot Lines and Clinical Trial Updates. European Society of Cardiology. ESC Congress Reports: Доступно на: http://www.escardio.org/knowledge/congresses/CongressReports/hotlinesandctus/707009_Camenzi nd.htm. Accessed December 17, 2006.
  637. Ferraris VA, Ferraris SP, Moliterno DJ, et al. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary) Ann Thorac Surg 2005;79:1454-1461.
  638. RITA Trial Participants Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial Lancet 1993;341:573-580.
  639. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration(published erratum appears in Lancet 1994;344:1446) Lancet 1994;344:563-570.
  640. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina N Engl J Med 1984;311:1333-1339.
  641. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgerySurvival data. Circulation 1983;98:939-950.
  642. De Feyter PJ, Serruys PW, Arnold A, et al. Coronary angioplasty of the unstable angina related vessel in patients with multivessel disease Eur Heart J 1986;7:460-467.
  643. Mock MB, Fisher LD, Holmes DRJ, et al. Comparison of effects of medical and surgical therapy on survival in severe angina pectoris and two-vessel coronary artery disease with and without left ventricular dysfunction: a Coronary Artery Surgery Study Registry Study Am J Cardiol 1988;61:1198-1203.
  644. Gluckman TJ, Sachdev M, Schulman SP, Blumenthal RS. A simplified approach to the management of non-ST-segment elevation acute coronary syndromes JAMA 2005;293:349-357.
  645. Beckie T. A supportive-educative telephone program: impact on knowledge and anxiety after coronary artery bypass graft surgery Heart Lung 1989;18:46-55.
  646. U.S. Centers for Disease Control and Prevention State-Specific Prevalence of Obesity Among Adults—United States, 2005 MMWR 2006;55:985-988. Доступно на: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5536a1.htm. Accessed November 27, 2006.
  647. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes Circulation 2004;109:745-749.
  648. Mukherjee D, Fang J, Kline-Rogers E, Otten R, Eagle KA. Impact of combination evidence based medical treatment in patients with acute coronary syndromes in various TIMI risk groups Heart 2005;91:381-382.
  649. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 2003;362:782-788.
  650. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 2004;351:2058-2068.
  651. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials Lancet 2006;368:581-588.
  652. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction —may they rest in PEACE? N Engl J Med 2004;351:2115-2117.
  653. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344:1383-1389.
  654. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 1998;339:1349-1357.
  655. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 1996;335:1001-1009.
  656. Heart Protection Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002;360:7-22.
  657. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 2004;292:1307-1316.
  658. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 2004;350:1495-1504.
  659. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 2006;295:1556-1565.
  660. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival JAMA 2001;285:430-436.
  661. Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short­term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials JAMA 2006;295:2046-2056.
  662. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality Am J Cardiol 2001;87:257-261.
  663. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) Am J Cardiol 2001;87:819-822.
  664. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now Circulation 2001;103:2768-2770.
  665. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction JAMA 2007;297:177- 186.
  666. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 2003;42:1206-1252.
  667. Rosendorff C, Black HR, Cannon CP, et al. American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation 2007;115:2761-2788.
  668. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 2002;346:393-403.
  669. Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition recommendations and interventions for diabetes—2006: a position statement of the American Diabetes Association Diabetes Care 2006;29:2140-2157.
  670. Summary of revisions for the 2006 Clinical Practice Recommendations Diabetes Care 2006;29(Suppl 1):S3.
  671. Daly LE, Mulcahy R, Graham IM, Hickey N. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction Br Med J (Clin Res Ed) 1983;287:324- 326.
  672. U.S. Department of Health and Human Services, Public Health Service Agency. Clinical Practice Guidelines: Number 18: Smoking Cessation. 1996; AHCPR Publication 96-0692.
  673. U.S. Department of Heath and Human Services. Physical Activity Fundamental to Preventing Disease. Office of the Assistant Secretary for Planning and Evaluation. Доступно на: http://aspe.hhs.gov/health/reports/physicalactivity/. Accessed October 10, 2006.
  674. Thompson PD. Exercise prescription and proscription for patients with coronary artery disease Circulation 2005;112:2354-2363.
  675. Gondoni LA, Liuzzi A, Titon AM, et al. A simple tool to predict exercise capacity of obese patients with ischaemic heart disease Heart 2006;92:899-904.
  676. Rankin SL, Briffa TG, Morton AR, Hung J. A specific activity questionnaire to measure the functional capacity of cardiac patients Am J Cardiol 1996;77:1220-1223.
  677. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index) Am J Cardiol 1989;64:651-654.
  678. Morris CK, Myers J, Froelicher VF, Kawaguchi T, Ueshima K, Hideg A. Nomogram based on metabolic equivalents and age for assessing aerobic exercise capacity in men J Am Coll Cardiol 1993;22:175-182.
  679. Wenger NK, Froelicher ES, Smith LK, et al. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute Cardiac rehabilitation as secondary prevention Clin Pract Guidel Quick Ref Guide Clin 1995:1-23.
  680. Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: benefits and recommendations for physical activity programs for all AmericansA statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996;94:857-862.
  681. Pate RR, Pratt M, Blair SN, et al. Physical activity and public healthA recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402-407.
  682. Pollock ML, Franklin BA, Balady GJ, et al. AHA Science AdvisoryResistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; position paper endorsed by the American College of Sports Medicine. Circulation 2000;101:828-833.
  683. Flaker GC, Warnica JW, Sacks FM, et al. Cholesterol and Recurrent Events CARE Investigators Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations J Am Coll Cardiol 1999;34:106-112.
  684. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs. An update for cliniciansA scientific statement from the American Heart Association. Circulation 2007;115:1634-1642.
  685. Hulley S, Grady D, Bush T, et al. Heart and Estrogen/progestin Replacement Study (HERS) Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 1998;280:605-613.
  686. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 2003;349:523-534.
  687. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women JAMA 2004;292:2849-2859.
  688. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial JAMA 2002;288:321-333.
  689. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians JAMA 1992;268:877-881.
  690. Sullivan AK, Holdright DR, Wright CA, Sparrow JL, Cunningham D, Fox KM. Chest pain in women: clinical, investigative, and prognostic features BMJ 1994;308:883-886.
  691. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease N Engl J Med 2006;354:1567-1577.
  692. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction N Engl J Med 2006;354:1578-1588.
  693. Bjelakovic G, Dimitrinka N, Gluud L, Simonetti R, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systemic review and meta­analysis JAMA 2007;297:842-857.
  694. Schechtman KB, Capone RJ, Kleiger RE, et al. The Diltiazem Reinfarction Study Research Group Risk stratification of patients with non-Q wave myocardial infarction: the critical role of ST segment depression Circulation 1989;80:1148-1158.
  695. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina BMJ 1996;313:262-264.
  696. Newby LK, Christenson RH, Ohman EM, et al. The GUSTO-IIa Investigators Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes Circulation 1998;98:1853-1859.
  697. van Domburg RT, Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course J Am Coll Cardiol 1998;31:1534-1539.
  698. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society J Am Coll Cardiol 2006;48:e247-e346.
  699. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation J Am Coll Cardiol 2006;47:1239-1312.
  700. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction(published erratum appears in Circulation 1998;97:708) Circulation 1995;91:999-1005.
  701. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina JAMA 2002;288:701-709.
  702. Carney RM, Blumenthal JA, Freedland KE, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study Psychosom Med 2004;66:466-474.
  703. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial JAMA 2007;297:367-379.
  704. Demyttenaere K. Risk factors and predictors of compliance in depression Eur Neuropsychopharmacol 2003;13(Suppl 3):S69-S75.
  705. Stromberg A, Brostrom A, Dahlstrom U, Fridlund B. Factors influencing patient compliance with therapeutic regimens in chronic heart failure: a critical incident technique analysis Heart Lung 1999;18:334-341.
  706. Rosenstock IM. Adoption and maintenance of lifestyle modifications Am J Prev Med 1988;4:349-352.
  707. Balady GJ, Ades PA, Comoss P, et al. Core components of cardiac rehabilitation/secondary prevention programs: a statement for healthcare professionals from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group Circulation 2000;102:1069-1073.
  708. King ML, Williams MA, Fletcher GF, et al. Medical director responsibilities for outpatient cardiac rehabilitation/secondary prevention programs: a scientific statement from the American Heart Association/American Association for Cardiovascular and Pulmonary Rehabilitation Circulation 2005;112:3354-3360.
  709. Feigenbaum E and Carter, E. Heath Technology Assessment Report No. 6. US Department of Health and Human Services. Public Health Service. National Center for Health Services, Research, and Health Care Technology Assessment. Publication No. PHS 883427, 1988.
  710. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease Cochrane Database Syst Rev 2001CD001800.
  711. DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction Ann Intern Med 1994;120:721-729.
  712. Witt BJ, Jacobsen SJ, Weston SA, et al. Cardiac rehabilitation after myocardial infarction in the community J Am Coll Cardiol 2004;44:988-996.
  713. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarctionCombined experience of randomized clinical trials. JAMA 1988;260:945-950.
  714. Ades PA, Pashkow FJ, Nestor JR. Cost-effectiveness of cardiac rehabilitation after myocardial infarction J Cardiopulm Rehabil 1997;17:222-231.
  715. Bondestam E, Breikss A, Hartford M. Effects of early rehabilitation on consumption of medical care during the first year after acute myocardial infarction in patients > or = 65 years of age Am J Cardiol 1995;75:767-771.
  716. Cohen MG, Roe MT, Mulgund J, et al. Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) Am Heart J 2006;152:110-117.
  717. Barber K, Stommel M, Kroll J, Holmes-Rovner M, McIntosh B. Cardiac rehabilitation for community-based patients with myocardial infarction: factors predicting discharge recommendation and participation J Clin Epidemiol 2001;54:1025-1030.
  718. Spencer FA, Salami B, Yarzebski J, Lessard D, Gore JM, Goldberg RJ. Temporal trends and associated factors of inpatient cardiac rehabilitation in patients with acute myocardial infarction: a community-wide perspective J Cardiopulm Rehabil 2001;21:377-384.
  719. O’Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction Circulation 1989;80:234-244.
  720. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training programs in patients > or = 75 years of age Am J Cardiol 1996;78:675-677.
  721. Ziegelstein RC. Depression in patients recovering from a myocardial infarction JAMA 2001;286:1621-1627.
  722. Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention Circulation 2002;105:1735-1743.
  723. Centers for Medicare & Medicaid Services. Your Medicare Benefits. Доступно на: http://www.medicare.gov/Publications/Pubs/pdf/10116.pdf. Accessed October 27, 2006.
  724. Rost K, Smith GR. Return to work after an initial myocardial infarction and subsequent emotional distress Arch Intern Med 1992;152:381-385.
  725. Froelicher ES, Kee LL, Newton KM, Lindskog B, Livingston M. Return to work, sexual activity, and other activities after acute myocardial infarction Heart Lung 1994;23:423-435.
  726. Lewin R. Return to work after MI, the roles of depression, health beliefs and rehabilitation Int J Cardiol 1999;72:49-51.
  727. Grines CL, Marsalese DL, Brodie B, et al. PAMI-II Investigators Safety and cost- effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarctionPrimary Angioplasty in Myocardial Infarction. J Am Coll Cardiol 1998;31:967-972.
  728. Petrie KJ, Cameron LD, Ellis CJ, Buick D, Weinman J. Changing illness perceptions after myocardial infarction: an early intervention randomized controlled trial Psychosom Med 2002;64:580-586.
  729. Ostir GV, Goodwin JS, Markides KS, Ottenbacher KJ, Balfour J, Guralnik JM. Differential effects of premorbid physical and emotional health on recovery from acute events J Am Geriatr Soc 2002;50:713-718.
  730. Sansone GR, Alba A, Frengley JD. Analysis of FIM instrument scores for patients admitted to an inpatient cardiac rehabilitation program Arch Phys Med Rehabil 2002;83:506-512.
  731. Froom P, Cohen C, Rashcupkin J, et al. Referral to occupational medicine clinics and resumption of employment after myocardial infarction J Occup Environ Med 1999;41:943-947.
  732. Boudrez H, De BG. Recent findings on return to work after an acute myocardial infarction or coronary artery bypass grafting Acta Cardiol 2000;55:341-349.
  733. Mittag O, Kolenda KD, Nordman KJ, Bernien J, Maurischat C. Return to work after myocardial infarction/coronary artery bypass grafting: patients’ and physicians’ initial viewpoints and outcome 12 months later Soc Sci Med 2001;52:1441-1450.
  734. Kavanagh T, Matosevic V, Thacker L, Belliard R, Shephard RJ. On-site evaluation of bus drivers with coronary heart disease J Cardiopulm Rehabil 1998;18:209-215.
  735. Covinsky KE, Chren MM, Harper DL, Way LE, Rosenthal GE. Differences in patient- reported processes and outcomes between men and women with myocardial infarction J Gen Intern Med 2000;15:169-174.
  736. Antman EM, Kuntz KM. The length of the hospital stay after myocardial infarction N Engl J Med 2000;342:808-810.
  737. Haskell WL. Rehabilitation of the coronary patientIn: Wenger NK, Hellerstein HK, editors. Design and Implantation of Cardiac Conditioning Program. New York, NY: Churchill Livingstone; 1978. pp. 147.
  738. Usher M, Dennis C, Schwartz R, Ahn D, DeBusk RF. Physician influences on timing of return to work after myocardial infarction Circulation 1986:74.
  739. Petrucelli E, Manilowski M. Status of Medical Review in Drier Liscensing: Policies, Programs and Standards. Springfield, VA: National Highway Traffic Safety Administration, US Dept of Transportation;992. DOT HS 807 892.
  740. Code of Federal Regulation 14CFR 121. Pg 427, Section 25.841. Published by the Office of Federal Register. January 1, 2002.
  741. Code of Federal Regulation 14 CFR 121. Appendix A:555-7. Published by the Office of the Federal Register. January 1, 2002.
  742. Cannon RO, Camici PG, Epstein SE. Pathophysiological dilemma of syndrome X Circulation 1992;85:883-892.
  743. DeSanctis RW. Clinical manifestations of coronary artery disease: chest pain in womenIn: Wenger NK, Speroff L, Packard B, editors. Cardiovascular Health and Disease in Women. Greenwich, CT: Le Jacq Communications, Inc; 1993. pp. 67.
  744. Shaw LJ, Olson MB, Kip K, et al. The value of estimated functional capacity in estimating outcome: results from the NHBLI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study J Am Coll Cardiol 2006;47:S36-S43.
  745. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry JAMA 1996;275:1104-1112.
  746. Keelan ET, Nunez BD, Grill DE, Berger PB, Holmes DRJ, Bell MR. Comparison of immediate and long-term outcome of coronary angioplasty performed for unstable angina and rest pain in men and women Mayo Clin Proc 1997;72:5-12.
  747. Robertson T, Kennard ED, Mehta S, et al. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the New Approaches to Coronary Intervention (NACI) registry Am J Cardiol 1997;80:26K-39K.
  748. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative J Am Coll Cardiol 2005;45:832- 837.
  749. DeVon HA, Zerwic JJ. Symptoms of acute coronary syndromes: are there gender differences? A review of the literature Heart Lung 2002;31:235-245.
  750. Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS- TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy Circulation 2004;109:580-586.
  751. Califf RM, DeLong ER, Ostbye T, et al. Underuse of aspirin in a referral population with documented coronary artery disease Am J Cardiol 2002;89:653-661.
  752. Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease Ann Intern Med 1994;120:559-566.
  753. Lansky AJ, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association Circulation 2005;111:940-953.
  754. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes JAMA 2005;294:3108-3116.
  755. Brosius III FC, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation Circulation 2006; 114:1083-1087.
  756. Cowley MJ, Mullin SM, Kelsey SF, et al. Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry Circulation 1985;71:90-97.
  757. Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley MJ, Detre KM. Results of percutaneous transluminal coronary angioplasty in women: 1985-1986 National Heart, Lung, and Blood Institute’s Coronary Angioplasty Registry Circulation 1993;87:720-727.
  758. Bell MR, Holmes DRJ, Berger PB, Garratt KN, Bailey KR, Gersh BJ. The changing in­hospital mortality of women undergoing percutaneous transluminal coronary angioplasty JAMA 1993;269:2091-2095.
  759. Fisher LD, Kennedy JW, Davis KB, et al. Association of sex, physical size, and operative mortality after coronary artery bypass in the Coronary Artery Surgery Study (CASS) J Thorac Cardiovasc Surg 1982;84:334-341.
  760. Loop FD, Golding LR, MacMillan JP, Cosgrove DM, Lytle BW, Sheldon WC. Coronary artery surgery in women compared with men: analyses of risks and long-term results J Am Coll Cardiol 1983;1:383-390.
  761. Arnold AM, Mick MJ, Piedmonte MR, Simpfendorfer C. Gender differences for coronary angioplasty Am J Cardiol 1994;74:18-21.
  762. Weintraub WS, Wenger NK, Kosinski AS, et al. Percutaneous transluminal coronary angioplasty in women compared with men J Am Coll Cardiol 1994;24:81-90.
  763. Welty FK, Mittleman MA, Healy RW, Muller JE, Shubrooks SJJ. Similar results of percutaneous transluminal coronary angioplasty for women and men with postmyocardial infarction ischemia J Am Coll Cardiol 1994;23:35-39.
  764. Eysmann SB, Douglas PS. Coronary heart disease: therapeutic principlesIn: Douglas PS, editor. Cardiovascular Health and Disease in Women. Philadelphia, PA: W.B. Saunders Company; 1993. pp.43.
  765. Jacobs AK, Kelsey SF, Yeh W, et al. National Heart, Lung, and Blood Institute Documentation of decline in morbidity in women undergoing coronary angioplasty (a report from the 1993-94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry) Am J Cardiol 1997;80:979-984.
  766. Mikhail GW. Coronary revascularisation in women Heart 2006;92(Suppl 3):iii19-iii23.
  767. Lansky AJ. Outcomes of percutaneous and surgical revascularization in women Prog Cardiovasc Dis 2004;46:305-319.
  768. Humphries KH, Gao M, Pu A, Lichtenstein S, Thompson CR. Significant improvement in short-term mortality in women underging coronary artery bypass surgery (1991 to 2004) J Am Coll Cardiol 2007;49:1552-1558.
  769. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 1998;98:1279-1285.
  770. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trialRandomized Intervention Trial of unstable Angina. Lancet 2002;360:743-751.
  771. Cannon CP, Weintraub WS, Demopoulos LA, et al. TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)- Thrombolysis in Myocardial Infarction 18 Investigators Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 2001;344:1879-1887.
  772. Morise AP, Diamond GA. Comparison of the sensitivity and specificity of exercise electrocardiography in biased and unbiased populations of men and women Am Heart J 1995;130:741-747.
  773. Williams MJ, Marwick TH, O’Gorman D, Foale RA. Comparison of exercise echocardiography with an exercise score to diagnose coronary artery disease in women Am J Cardiol 1994;74:435-438.
  774. Robert AR, Melin JA, Detry JM. Logistic discriminant analysis improves diagnostic accuracy of exercise testing for coronary artery disease in women Circulation 1991;83:1202-1209.
  775. Shaw LJ, Hendel R, Borges-Neto S, et al. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients J Nucl Med 2003;44:134-139.
  776. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association Circulation 2005;111:682-696.
  777. Alexander KP, Shaw LJ, DeLong ER, Mark DB, Peterson ED. Value of exercise treadmill testing in women J Am Coll Cardiol 1998;32:1657-1664.
  778. Lewis JF, Lin L, McGorray S, et al. Dobutamine stress echocardiography in women with chest pain: pilot phase data from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE) J Am Coll Cardiol 1999;33:1462-1468.
  779. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies J Am Coll Cardiol 2006;47:S4-S20.
  780. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease J Am Coll Cardiol 2006;47:S21-S29.
  781. Gierach GL, Johnson BD, Bairey Merz CN, et al. Hypertension, menopause, and coronary artery disease risk in the Women’s Ischemia Syndrome Evaluation (WISE) study J Am Coll Cardiol 2006;47:S50-S58.
  782. Handberg E, Johnson BD, Arant CB, et al. Impaired coronary vascular reactivity and functional capacity in women: results from the NHLBI Women’s Ischemia Syndrome Evaluation (WISE) study J Am Coll Cardiol 2006;47:S44-S49.
  783. Pepine CJ, Kerensky RA, Lambert CR, et al. Some thoughts on the vasculopathy of women with ischemic heart disease J Am Coll Cardiol 2006;47:S30-S35.
  784. Lerman A, Sopko G. Women and cardiovascular heart disease: clinical implications from the Women’s Ischemia Syndrome Evaluation (WISE) study. Are we smarter? J Am Coll Cardiol 2006;47:S59-S62.
  785. Jacobs AK. Women, ischemic heart disease, revascularization, and the gender gap: what are we missing? J Am Coll Cardiol 2006;47:S63-S65.
  786. Quyyumi AA. Women and ischemic heart disease: pathophysiologic implications from the Women’s Ischemia Syndrome Evaluation (WISE) study and future research steps J Am Coll Cardiol 2006;47:S66-S71.
  787. Bittl JA, Strony J, Brinker JA, et al. Hirulog Angioplasty Study Investigators Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina N Engl J Med 1995;333:764-769.
  788. Influence of diabetes on 5- year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 1997;96:1761-1769.
  789. Theroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable anginaThe Canadian Lamifiban Study. Circulation 1996;94:899-905.
  790. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial Circulation 1994;89:1557-1566.
  791. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry Circulation 1996;94:1818-1825.
  792. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty Circulation 1995;91:979-989.
  793. Wilcox I, Freedman SB, Allman KC, et al. Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris J Am Coll Cardiol 1991;18:677-683.
  794. Karlson BW, Herlitz J, Pettersson P, Hallgren P, Strombom U, Hjalmarson A. One-year prognosis in patients hospitalized with a history of unstable angina pectoris Clin Cardiol 1993;16:397-402.
  795. Fava S, Azzopardi J, Agius-Muscat H. Outcome of unstable angina in patients with diabetes mellitus Diabet Med 1997;14:209-213.
  796. Garcia-Rubira JC, Cruz JM, Lopez V, Plaza L, Navas JC, Grupo de Estudio del Trifusal en la Angina Inestable Outcome of patients with diabetes and unstable angina: a subgroup analysis in the Spanish Multicentre Trial of trifusal in unstable angina Int J Cardiol 1994;46:175-178.
  797. Theroux P, Waters D. Unstable angina: special considerations in the post-bypass patientIn: Waters D, Bourassa MG, Brest AN, editors. Care of the Patient with Previous Coronary Bypass Surgery. Philadelphia, PA: FA Davis; 1991. pp. 169-191.
  798. Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes J Am Coll Cardiol 1993;22:1433-1437.
  799. Ambepityia G, Kopelman PG, Ingram D, Swash M, Mills PG, Timmis AD. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function J Am Coll Cardiol 1990;15:72-77.
  800. Zola B, Kahn JK, Juni JE, Vinik AI. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease J Clin Endocrinol Metab 1986;63:208-214.
  801. Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ. Unstable angina: a comparison of angioscopic findings between diabetic and nondiabetic patients Circulation 1995;92:1731-1736.
  802. Position statements and ADA statements Diabetes Care 2006;29(Suppl 1):S75-S77.
  803. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA. Impaired glucose metabolism predicts mortality after a myocardial infarction Int J Cardiol 2001;79:207-214.
  804. Malmberg K, DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus BMJ 1997;314:1512- 1515.
  805. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year J Am Coll Cardiol 1995;26:57-65.
  806. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity Eur Heart J 2005;26:650-661.
  807. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures Ann Thorac Surg 1999;67:352-360.
  808. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting J Thorac Cardiovasc Surg 2003;125:1007-1021.
  809. Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes Diabetes Care 1999;22:1408- 1414.
  810. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control Crit Care Med 2003;31:359-366.
  811. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview Lancet 2000;355:773-778.
  812. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients N Engl J Med 2001;345:1359-1367.
  813. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU N Engl J Med 2006;354:449-461.
  814. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia Crit Care Clin 2001;17:107-124.
  815. Malhotra A. Intensive insulin in intensive care N Engl J Med 2006;354:516-518.
  816. Jones EL, Weintraub WS, Craver JM, Guyton RA, Cohen CL. Coronary bypass surgery: is the operation different today? J Thorac Cardiovasc Surg 1991;101:108-115.
  817. King III SB, Kosinski A, Guyton RA, Lembo NJ, Weintraub WS. Eight year mortality in the Emory Angioplasty vs Surgery Trial (EAST) J Am Coll Cardiol 2000;35:1116-1121.
  818. Kuntz RE. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma Circulation 1999;99:847-851.
  819. Barsness GW, Peterson ED, Ohman EM, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty Circulation 1997;96:2551-2556.
  820. Levine GN, Jacobs AK, Keeler GP, et al. CAVEAT-I Investigators Impact of diabetes mellitus on percutaneous revascularization (CAVEAT- I)Coronary Angioplasty Versus Excisional Atherectomy Trial. Am J Cardiol 1997;79:748-755.
  821. Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England Circulation 2005;112:I371-I376.
  822. Kleiman NS, Lincoff AM, Kereiakes DJ, et al. EPILOG Investigators Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial Circulation 1998;97:1912-1920.
  823. Theroux P, Alexander Jr. J, Pharand C, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study Circulation 2000;102:2466-2472.
  824. Lincoff AM, Califf RM, Anderson KM, et al. EPIC Investigators Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularizationEvaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1997;30:149-156.
  825. Topol EJ, Mark DB, Lincoff AM, et al. EPISTENT Investigators Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trialEvaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354:2019-2024.
  826. Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up Circulation 2002;105:2730-2736.
  827. Lambert M, Kouz S, Campeau L. Preoperative and operative predictive variables of late clinical events following saphenous vein coronary artery bypass graft surgery Can J Cardiol 1989;5:87-92.
  828. Waters DD, Walling A, Roy D, Theroux P. Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris Am J Cardiol 1986;58:465-469.
  829. Grondin CM, Campeau L, Lesperance J, Enjalbert M, Bourassa MG. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation Circulation 1984;70:I208-I212.
  830. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts: morphologic study and risk factor analysis 6 to 12 years after surgery Arteriosclerosis 1986;6:594-600.
  831. Waller BF, Rothbaum DA, Gorfinkel HJ, Ulbright TM, Linnemeier TJ, Berger SM. Morphologic observations after percutaneous transluminal balloon angioplasty of early and late aortocoronary saphenous vein bypass grafts J Am Coll Cardiol 1984;4:784-792.
  832. Walts AE, Fishbein MC, Sustaita H, Matloff JM. Ruptured atheromatous plaques in saphenous vein coronary artery bypass grafts: a mechanism of acute, thrombotic, late graft occlusion Circulation 1982;65:197-201.
  833. Hwang MH, Meadows WR, Palac RT, et al. Progression of native coronary artery disease at 10 years: insights from a randomized study of medical versus surgical therapy for angina J Am Coll Cardiol 1990;16:1066-1070.
  834. Chen L, Theroux P, Lesperance J, Shabani F, Thibault B, de Guise P. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery J Am Coll Cardiol 1996;28:1493-1499.
  835. Waters DD, Theroux P, Crittin J, Dauwe F, Mizgala HF. Previously undiagnosed variant angina as a cause of chest pain after coronary artery bypass surgery Circulation 1980;61:1159-1164.
  836. Baduini G, Marra S, Angelino PF. Sudden occlusion of a saphenous vein bypass graft relieved by direct injection of nitroglycerin Cathet Cardiovasc Diagn 1981:787-795.
  837. Lawrie GM, Morris GCJ, Silvers A, et al. The influence of residual disease after coronary bypass on the 5-year survival rate of 1274 men with coronary artery disease Circulation 1982;66:717-723.
  838. Silva JA, White CJ, Collins TJ, Ramee SR. Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina Am Heart J 1998;136:156-163.
  839. Ritchie JL, Narahara KA, Trobaugh GB, Williams DL, Hamilton GW. Thallium-201 myocardial imaging before and after coronary revascularization: assessment of regional myocardial blood flow and graft patency Circulation 1977;56:830-836.
  840. Verani MS, Marcus ML, Spoto G, Rossi NP, Ehrhardt JC, Razzak MA. Thallium-201 myocardial perfusion scintigrams in the evaluation of aorto-coronary saphenous bypass surgery J Nucl Med 1978;19:765-772.
  841. Carlino M, De Gregorio J, di Mario C, et al. Prevention of distal embolization during saphenous vein graft lesion angioplastyExperience with a new temporary occlusion and aspiration system. Circulation 1999;99:3221-3223.
  842. Kleiman NS, Anderson HV, Rogers WJ, Theroux P, Thompson B, Stone PH. Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry) Am J Cardiol 1996;77:227-231.
  843. Savage MP, Douglas JSJ, Fischman DL, et al. Saphenous Vein De Novo Trial Investigators Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts N Engl J Med 1997;337:740-747.
  844. Alexander KP, Roe MT, Chen AY, et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative J Am Coll Cardiol 2005;46:1479-1487.
  845. Nadelmann J, Frishman WH, Ooi WL, et al. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: the Bronx Aging Study Am J Cardiol 1990;66:533-537.
  846. Lakatta EG, Gerstenblith G, Weisfeldt ML. The aging heart: structure, function, and diseaseIn: Braunwald E, editor. Heart Disease. Philadelphia, PA: W.B. Saunders Company; 1997. pp. 1687-1703.
  847. Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE) Am Heart J 2005;149:67-73.
  848. Stein B, Kupersmith J. Principles and practice of pharmacotherapyIn: Kupersmith J, Deedwania PC, editors. The Pharmacologic Management of Heart Disease. Baltimore, MD: Williams and Wilkins; 1997. pp. 3-38.
  849. Vasilomanolakis EC. Geriatric cardiology: when exercise stress testing is justified Geriatrics 1985;40:47-5053-4, 57.
  850. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromesResults from the CRUSADE Quality Improvement Initiative. JAMA 2004;292:2096-2104.
  851. Thompson RC, Holmes DRJ, Grill DE, Mock MB, Bailey KR. Changing outcome of angioplasty in the elderly J Am Coll Cardiol 1996;27:8-14.
  852. Thompson RC, Holmes DRJ, Gersh BJ, Bailey KR. Predicting early and intermediate-term outcome of coronary angioplasty in the elderly Circulation 1993;88:1579-1587.
  853. Nasser TK, Fry ET, Annan K, et al. Comparison of six-month outcome of coronary artery stenting in patients <65, 65-75, and >75 years of age Am J Cardiol 1997;80:998-1001.
  854. Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes Ann Intern Med 2004;141:186-195.
  855. Ivanov J, Weisel RD, David TE, Naylor CD. Fifteen-year trends in risk severity and operative mortality in elderly patients undergoing coronary artery bypass graft surgery Circulation 1998;97:673-680.
  856. Peterson ED, Jollis JG, Bebchuk JD, et al. Changes in mortality after myocardial revascularization in the elderly: the national Medicare experience Ann Intern Med 1994; 121:919­927.
  857. Freeman WK, Schaff HV, O’Brien PC, Orszulak TA, Naessens JM, Tajik AJ. Cardiac surgery in the octogenarian: perioperative outcome and clinical follow-up J Am Coll Cardiol 1991;18:29-35.
  858. Kaul TK, Fields BL, Wyatt DA, Jones CR, Kahn DR. Angioplasty versus coronary artery bypass in octogenarians Ann Thorac Surg 1994;58:1419-1426.
  859. Ko W, Gold JP, Lazzaro R, et al. Survival analysis of octogenarian patients with coronary artery disease managed by elective coronary artery bypass surgery versus conventional medical treatment Circulation 1992;86:II191-II197.
  860. Glower DD, Christopher TD, Milano CA, et al. Performance status and outcome after coronary artery bypass grafting in persons aged 80 to 93 years Am J Cardiol 1992;70:567-571.
  861. Bridges CR, Edwards FH, Peterson ED, Coombs LP, Ferguson TB. Cardiac surgery in nonagenarians and centenarians J Am Coll Surg 2003;197:347-356.
  862. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N Engl J Med 2004;351:1285-1295.
  863. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 2004;351:1296-1305.
  864. Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality Am J Kidney Dis 2004;44:198-206.
  865. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial J Am Coll Cardiol 2006;48:924-930.
  866. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media J Am Coll Cardiol 2006;48:692- 699.
  867. Chakko S, Myerburg RJ. Cardiac complications of cocaine abuse Clin Cardiol 1995;18:67- 72.
  868. Isner JM, Chokshi SK. Cardiovascular complications of cocaine Curr Probl Cardiol 1991;16:89-123.
  869. Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart Circulation 1992;85:407-419.
  870. Pitts WR, Lange RA, Cigarroa JE, Hillis LD. Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management Prog Cardiovasc Dis 1997;40:65-76.
  871. Lange RA, Flores ED, Cigarroa RG, Hillis LD. Cocaine-induced myocardial ischemia Cardio 1990;7:74-7578-79.
  872. Loper KA. Clinical toxicology of cocaine Med Toxicol Adverse Drug Exp 1989;4:174-185.
  873. Flores ED, Lange RA, Cigarroa RG, Hillis LD. Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: enhanced vasoconstriction at sites of significant stenoses J Am Coll Cardiol 1990;16:74-79.
  874. Lange RA, Cigarroa RG, Yancy CWJ, et al. Cocaine-induced coronary-artery vasoconstriction N Engl J Med 1989;321:1557-1562.
  875. Zimmerman FH, Gustafson GM, Kemp HGJ. Recurrent myocardial infarction associated with cocaine abuse in a young man with normal coronary arteries: evidence for coronary artery spasm culminating in thrombosis J Am Coll Cardiol 1987;9:964-968.
  876. Bedotto JB, Lee RW, Lancaster LD, Olajos M, Goldman S. Cocaine and cardiovascular function in dogs: effects on heart and peripheral circulation J Am Coll Cardiol 1988;11:1337-1342.
  877. Brogan WC, Lange RA, Kim AS, Moliterno DJ, Hillis LD. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin J Am Coll Cardiol 1991;18:581-586.
  878. Isner JM, Chokshi SK. Cocaine and vasospasm N Engl J Med 1989;321:1604-1606.
  879. Nademanee K, Gorelick DA, Josephson MA, et al. Myocardial ischemia during cocaine withdrawal Ann Intern Med 1989; 111:876-880.
  880. Vitullo JC, Karam R, Mekhail N, Wicker P, Engelmann GL, Khairallah PA. Cocaine- induced small vessel spasm in isolated rat hearts Am J Pathol 1989;135:85-91.
  881. Togna G, Tempesta E, Togna AR, Dolci N, Cebo B, Caprino L. Platelet responsiveness and biosynthesis of thromboxane and prostacyclin in response to in vitro cocaine treatment Haemostasis 1985;15:100-107.
  882. Chokshi SK, Pitcairn LM. Cocaine and cardiovascular diseases: leading edge Cardiol 1989;3:1-6.
  883. Stenberg RG, Winniford, MD, Hillis LD, Dowling GP, Buja LM. Simultaneous acute thrombosis of two major coronary arteries following intravenous cocaine use Arch Pathol Lab Med 1989;113:521-524.
  884. Hollander JE, Brooks DE, Valentine SM. Assessment of cocaine use in patients with chest pain syndromes Arch Intern Med 1998;158:62-66.
  885. Gitter MJ, Goldsmith SR, Dunbar DN, Sharkey SW. Cocaine and chest pain: clinical features and outcome of patients hospitalized to rule out myocardial infarction Ann Intern Med 1991;115:277-282.
  886. Dressler FA, Malekzadeh S, Roberts WC. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts Am J Cardiol 1990;65:303-308.
  887. Virmani R, Robinowitz M, Smialek JE, Smyth DF. Cardiovascular effects of cocaine: an autopsy study of 40 patients Am Heart J 1988;115:1068-1076.
  888. Rashid J, Eisenberg MJ, Topol EJ. Cocaine-induced aortic dissection Am Heart J 1996;132:1301-1304.
  889. Willens HJ, Chakko SC, Kessler KM. Cardiovascular manifestations of cocaine abuse: a case of recurrent dilated cardiomyopathy Chest 1994;106:594-600.
  890. Chokshi SK, Moore R, Pandian NG, Isner JM. Reversible cardiomyopathy associated with cocaine intoxication Ann Intern Med 1989;111:1039-1040.
  891. Yao SS, Spindola-Franco H, Menegus M, Greenberg M, Goldberger M, Shirani J. Successful intracoronary thrombolysis in cocaine-associated acute myocardial infarction Cathet Cardiovasc Diagn 1997;42:294-297.
  892. Hollander JE. The management of cocaine-associated myocardial ischemia N Engl J Med 1995;333:1267-1272.
  893. Tokarski GF, Paganussi P, Urbanski R, Carden D, Foreback C, Tomlanovich MC. An evaluation of cocaine-induced chest pain Ann Emerg Med 1990;19:1088-1092.
  894. Hollander JE, Hoffman RS, Gennis P, et al. Cocaine Associated Chest Pain (COCHPA) Study Group Prospective multicenter evaluation of cocaine-associated chest pain Acad Emerg Med 1994;1:330-339.
  895. Weber JE, Shofer FS, Larkin GL, Kalaria AS, Hollander JE. Validation of a brief observation period for patients with cocaine-associated chest pain N Engl J Med 2003;348:510-517.
  896. Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta- adrenergic blockade Ann Intern Med 1990;112:897-903.
  897. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans Am J Med 1993;94:608-610.
  898. Furst SR, Fallon SP, Reznik GN, Shah PK. Myocardial infarction after inhalation of methamphetamine N Engl J Med 1990;323:1147-1148.
  899. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use J Emerg Med 2003;24:369-373.
  900. Wijetunga M, Bhan R, Lindsay J, Karch S. Acute coronary syndrome and crystal methamphetamine use: a case series Hawaii Med J 2004;63:8-1325.
  901. Watts DJ, McCollester L. Methamphetamine-induced myocardial infarction with elevated troponin I Am J Emerg Med 2006;24:132-134.
  902. Prinzmetal M, Goldman A, Shubin H, et al. Angina pectoris II Am Heart J 1959;57:530- 543.
  903. Ozaki Y, Keane D, Serruys PW. Fluctuation of spastic location in patients with vasospastic angina: a quantitative angiographic study J Am Coll Cardiol 1995;26:1606-1614.
  904. Yamagishi M, Miyatake K, Tamai J, Nakatani S, Koyama J, Nissen SE. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments J Am Coll Cardiol 1994;23:352-357.
  905. Maseri A, Severi S, Nes, MD, et al. "Variant" angina: one aspect of a continuous spectrum of vasospastic myocardial ischemiaPathogenetic mechanisms, estimated incidence and clinical and coronary arteriographic findings in 138 patients. Am J Cardiol 1978;42:1019-1035.
  906. Walling A, Waters DD, Miller DD, Roy D, Pelletier GB, Theroux P. Long-term prognosis of patients with variant angina Circulation 1987;76:990-997.
  907. Rovai D, Bianchi M, Baratto M, et al. Organic coronary stenosis in Prinzmetal’s variant angina J Cardiol 1997;30:299-305.
  908. Previtali M, Ardissino D, Barberis P, Panciroli C, Chimienti M, Salerno JA. Hyperventilation and ergonovine tests in Prinzmetal’s variant angina pectoris in men Am J Cardiol 1989;63:17-20.
  909. Matsuda Y, Ozaki M, Ogawa H, et al. Coronary arteriography and left ventriculography during spontaneous and exercise-induced ST segment elevation in patients with variant angina Am Heart J 1983;106:509-515.
  910. Raizner AE, Chahine RA, Ishimori T, et al. Provocation of coronary artery spasm by the cold pressor testHemodynamic, arteriographic and quantitative angiographic observations. Circulation 1980;62:925-932.
  911. Ogawa H, Yasue H, Oshima S, Okumura K, Matsuyama K, Obata K. Circadian variation of plasma fibrinopeptide A level in patients with variant angina Circulation 1989;80:1617-1626.
  912. Nobuyoshi M, Abe M, Nosaka H, et al. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant Am Heart J 1992;124:32- 38.
  913. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm Circulation 1993;87:76-79.
  914. Miller DD, Waters DD, Szlachcic J, Theroux P. Clinical characteristics associated with sudden death in patients with variant angina Circulation 1982;66:588-592.
  915. Fukai T, Koyanagi S, Takeshita A. Role of coronary vasospasm in the pathogenesis of myocardial infarction: study in patients with no significant coronary stenosis Am Heart J 1993;126:1305-1311.
  916. MacAlpin RN. Cardiac arrest and sudden unexpected death in variant angina: complications of coronary spasm that can occur in the absence of severe organic coronary stenosis Am Heart J 1993;125:1011-1017.
  917. Willerson JT, Hillis LD, Winniford M, Buja LM. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes J Am Coll Cardiol 1986;8:245-250.
  918. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina Circulation 1996;94:266-271.
  919. Yasue H, Touyama M, Kato H, Tanaka S, Akiyama F. Prinzmetal’s variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm: documentation by coronary arteriography Am Heart J 1976;91:148-155.
  920. Shephard JT, Katsie ZJ. Endothelium derived vasoactive factors: I endothelium-dependent relaxation Hypertension 1991;18(Suppl III):76-85.
  921. Yasue H, Horio Y, Nakamura N, et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm Circulation 1986;74:955-963.
  922. Katsumata N, Shimokawa H, Seto M, et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta Circulation 1997;96:4357-4363.
  923. Nakao K, Ohgushi M, Yoshimura M, et al. Hyperventilation as a specific test for diagnosis of coronary artery spasm Am J Cardiol 1997;80:545-549.
  924. Pepine CJ. Ergonovine echocardiography for coronary spasm: facts and wishful thinking J Am Coll Cardiol 1996;27:1162-1163.
  925. Opie LH. Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm Prog Cardiovasc Dis 1996;38:291-314.
  926. Chahine RA, Feldman RL, Giles TD, et al. Amlodipine Study 160 Group Randomized placebo-controlled trial of amlodipine in vasospastic angina J Am Coll Cardiol 1993;21:1365-1370.
  927. Lombardi M, Morales MA, Michelassi C, Moscarelli E, Distante A, L’Abbate A. Efficacy of isosorbide-5-mononitrate versus nifedipine in preventing spontaneous and ergonovine-induced myocardial ischaemia: a double-blind, placebo-controlled study Eur Heart J 1993;14:845-851.
  928. Yasue H, Takizawa A, Nagao M, et al. Long-term prognosis for patients with variant angina and influential factors Circulation 1988;78:1-9.
  929. Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X) Circulation 2004;109:568-572.
  930. Rosen SD, Uren NG, Kaski JC, Tousoulis D, Davies GJ, Camici PG. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X Circulation 1994;90:50-60.
  931. Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy JAMA 2005;293:477-484.
  932. Kaski JC, Rosano GM, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA. Cardiac syndrome X: clinical characteristics and left ventricular function: long-term follow-up study J Am Coll Cardiol 1995;25:807-814.
  933. Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm Lancet 1998;351:1165-1169.
  934. Camici PG, Marraccini P, Lorenzoni R, et al. Coronary hemodynamics and myocardial metabolism in patients with syndrome X: response to pacing stress J Am Coll Cardiol 1991;17:1461-1470.
  935. Kaski JC, Cox ID, Crook JR, et al. Coronary Artery Disease Research Group Differential plasma endothelin levels in subgroups of patients with angina and angiographically normal coronary arteries Am Heart J 1998;136:412-417.
  936. Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging N Engl J Med 2002;346:1948- 1953.
  937. Buchthal SD, den Hollander JA, Merz CN, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms N Engl J Med 2000;342:829-835.
  938. Anselmi M, Golia G, Marino P, et al. Comparison of left ventricular function and volumes during transesophageal atrial pacing combined with two-dimensional echocardiography in patients with syndrome X, atherosclerotic coronary artery disease, and normal subjects Am J Cardiol 1997;80:1261-1265.
  939. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study J Am Coll Cardiol 1986;7:479-483.
  940. Opherk D, Schuler G, Wetterauer K, Manthey J, Schwarz F, Kubler W. Four-year follow-up study in patients with angina pectoris and normal coronary arteriograms ("syndrome X") Circulation 1989;80:1610-1616.
  941. Cannon RO, Watson RM, Rosing DR, Epstein SE. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve Am J Cardiol 1985;56:242-246.
  942. Bugiardini R, Borghi A, Biagetti L, Puddu P. Comparison of verapamil versus propranolol therapy in syndrome X Am J Cardiol 1989;63:286-290.
  943. Maseri A. Ischemic Heart Disease: A Rationale Basis for Clinical Practice and Clinical Research. New York: Churchill Livingston; 1995.
  944. Galassi AR, Kaski JC, Pupita G, Vejar M, Crea F, Maseri A. Lack of evidence for alpha- adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X Am J Cardiol 1989;64:264-269.
  945. Cannon RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms N Engl J Med 1994;330:1411-1417.
  946. Chauhan A, Mullins PA, Petch MC, Schofield PM. Is coronary flow reserve in response to papaverine really normal in syndrome X? Circulation 1994;89:1998-2004.
  947. Eliasson T, Albertsson P, Hardhammar P, Emanuelsson H, Augustinsson LE, Mannheimer C. Spinal cord stimulation in angina pectoris with normal coronary arteriograms Coron Artery Dis 1993;4:819-827.
  948. Roque M, Heras M, Roig E, et al. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms J Am Coll Cardiol 1998;31:139-143.
  949. Rosano GM, Peters NS, Lefroy D, et al. 17-beta-Estradiol therapy lessens angina in postmenopausal women with syndrome X J Am Coll Cardiol 1996;28:1500-1505.
  950. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, Soydan I. Benefits of statin treatment in cardiac syndrome-X1 Eur Heart J 2003;24:1999-2005.
  951. Eriksson BE, Tyni-Lenne R, Svedenhag J, et al. Physical training in Syndrome X: physical training counteracts deconditioning and pain in Syndrome X J Am Coll Cardiol 2000;36:1619- 1625.
  952. Mayou RA, Bryant BM, Sanders D, Bass C, Klimes I, Forfar C. A controlled trial of cognitive behavioural therapy for non-cardiac chest pain Psychol Med 1997;27:1021-1031.
  953. Sharkey SW, Lesser JR, Zenovich AG, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States Circulation 2005;111:472-479.
  954. Tsuchihashi K, Ueshima K, Uchida T, et al. Angina Pectoris-Myocardial Infarction Investigations in Japan Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction J Am Coll Cardiol 2001;38:11-18.
  955. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction N Engl J Med 1980;303:897-902.
  956. Rentrop P, Blanke H, Karsch KR, Kaiser H, Kostering H, Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris Circulation 1981;63:307- 317.
  957. Ganz W, Buchbinder N, Marcus H, et al. Intracoronary thrombolysis in evolving myocardial infarction Am Heart J 1981;101:4-13.
  958. Anderson JL, Marshall HW, Bray BE, et al. A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction N Engl J Med 1983;308:1312-1318.
  959. Kennedy JW, Ritchie JL, Davis KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction N Engl J Med 1983;309:1477-1482.
  960. Libby P. Molecular bases of the acute coronary syndromes Circulation 1995;91:2844-2850.
  961. Ross R. Atherosclerosis—an inflammatory disease N Engl J Med 1999;340:115-126.
  962. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II Circulation 2003;108:1772-1778.
  963. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I Circulation 2003;108:1664-1672.
  964. Furman MI, Dauerman HL, Goldberg RJ, Yarzebski J, Lessard D, Gore JM. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective J Am Coll Cardiol 2001;37:1571-1580.
  965. Fox KA, Steg PG, Eagle KA, et al. GRACE Investigators Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006 JAMA 2007;297:1892-1900.
  966. Henry TD, Atkins JM, Cunningham MS, et al. ST-segment elevation myocardial infarction: recommendations on triage of patients to heart attack centers: is it time for a national policy for the treatment of ST-segment elevation myocardial infarction? J Am Coll Cardiol 2006;47:1339-1345.
  967. Nallamothu BK, Bates ER, Wang Y, Bradley EH, Krumholz HM. Driving times and distances to hospitals with percutaneous coronary intervention in the United States: implications for prehospital triage of patients with ST-elevation myocardial infarction Circulation 2006; 113:1189­1195.
  968. Jacobs AK. Regionalized care for patients with ST-elevation myocardial infarction: it’s closer than you think Circulation 2006;113:1159-1161.
  969. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 2007;297:159-168.
  970. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 2006;48:438-445.
  971. Williams SC, Koss RG, Morton DJ, Loeb JM. Performance of top-ranked heart care hospitals on evidence-based process measures Circulation 2006;114:558-564.


 
« Аритмии сердца (6)   Ведение пациентов с приобретенными пороками сердца »